

70014 U.S. PTO  
09/22/97

EXPRESS MAIL NO.: EM061 034 688US

**PENNIE & EDMONDS LLP**

COUNSELLORS AT LAW  
1155 Avenue of the Americas  
New York, N.Y. 10036-2711  
(212) 790-9090

ATTORNEY DOCKET NO. 3996-016 Date September 22, 1997

Assistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): **MAURICE ZAUDERER**

Executed on: **UNEXECUTED**

Title of Invention: **T CELLS SPECIFIC FOR TARGET ANTIGENS  
AND VACCINES BASED THEREON**

Pages of Specification **101 + ABSTRACT**

Sheets of Drawings **18**

**PATENT APPLICATION FEE VALUE**

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	40	-20	20	\$22.00 each	440.00
Independent	7	-3	4	\$80.00 each	320.00
Minimum Fee					770.00
Multiple Dependency Fee If Applicable (\$260.00)					260.00
<b>Total</b>					1,790.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					-
<b>Total Filing Fee</b>					<b>\$ 1,790.00</b>

Priority of application no. filed on in is claimed under 35 U.S.C. § 119.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

*Laura A. Coruzzi*  
Laura A. Coruzzi  
PENNIE & EDMONDS LLP

30,742  
(Reg. No.)

Enclosure

This form is not for use with re-issue, design or plant patent applications.

# T CELLS SPECIFIC FOR TARGET ANTIGENS AND VACCINES BASED THEREON

## TABLE OF CONTENTS

		<u>Page</u>
5	1. INTRODUCTION . . . . .	1
	2. BACKGROUND OF THE INVENTION . . . . .	1
	2.1. CANCER VACCINES . . . . .	3
	2.2. VACCINIA VECTORS . . . . .	6
10	3. SUMMARY OF THE INVENTION . . . . .	8
	3.1. ABBREVIATIONS . . . . .	9
	4. DESCRIPTION OF THE FIGURES . . . . .	10
	5. DETAILED DESCRIPTION OF THE INVENTION . . . . .	13
15	5.1. IDENTIFYING TARGET ANTIGENS FOR USE IN VACCINES . . . . .	17
	5.1.1. INDUCTION OF CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR HUMAN TUMORS AND THEIR USE TO SELECT DNA RECOMBINANTS THAT ENCODE TARGET EPITOPES . . . . .	17
20	5.1.2. SCREENING CYTOTOXIC LYMPHOCYTES GENERATED AGAINST PRODUCTS OF GENES DIFFERENTIALLY EXPRESSED IN TUMOR CELLS FOR ACTIVITY AGAINST AUTHENTIC TUMOR CELLS . . . . .	23
	5.2. VACCINE FORMULATIONS . . . . .	25
25	5.2.1. EXPRESSION OF THE TARGET EPITOPE IN PROCARYOTIC AND EUCARYOTIC EXPRESSION SYSTEMS . . . . .	25
	5.2.1.1. EUCARYOTIC AND PROCARYOTIC EXPRESSION VECTORS . . . . .	28
30	5.2.1.2. HOST CELLS . . . . .	29
	5.2.2. EXPRESSION OF TARGET EPITOPE IN RECOMBINANT VIRAL VACCINES . . . . .	31
	5.2.3. METHODS OF TREATMENT AND/OR VACCINATION	34
35	6. EXAMPLE: TRIMOLECULAR RECOMBINATION EMPLOYING MODIFIED VACCINIA VIRUS VECTORS TO MAKE EXPRESSION LIBRARIES . . . . .	40
	6.1. CONSTRUCTION OF THE VECTORS . . . . .	40

	<u>Page</u>
6.2. GENERATION OF AN INCREASED FREQUENCY OF VACCINIA VIRUS RECOMBINANTS . . . . .	41
6.3. CONSTRUCTION OF A REPRESENTATIVE CDNA LIBRARY IN VACCINIA VIRUS . . . . .	45
6.4. DISCUSSION . . . . .	48
5 7. EXAMPLE: INDUCTION OF CYTOTOXIC T CELLS SPECIFIC FOR HUMAN TUMORS IN HLA AND HUMAN CD8 TRANSGENIC MICE . . .	49
8. EXAMPLE: HIGH-THROUGHPUT STRATEGY FOR SELECTION OF DNA RECOMBINANTS FROM A LIBRARY THAT ENCODES THE TARGET EPITOPES OF SPECIFIC 10 CYTOTOXIC T CELLS . . . . .	53
8.1. METHODS AND RESULTS . . . . .	53
8.2. DISCUSSION . . . . .	55
9. EXAMPLE: IDENTIFICATION OF POTENTIAL TUMOR-SPECIFIC ANTIGENS THAT ARE DIFFERENTIALLY EXPRESSED IN TUMORS . . .	55
15 9.1. REPRESENTATIONAL DIFFERENCE ANALYSIS (RDA) . .	57
9.2. REPRESENTATIONAL DIFFERENCE ANALYSIS OF GENES THAT ENCODE POTENTIAL TUMOR IMMUNOGENS . . . . .	59
9.3. CHARACTERIZATION OF DIFFERENTIALLY EXPRESSED GENE SEQUENCE FROM RDA . . . . .	60
20 9.4. MODIFIED DIFFERENTIAL DISPLAY OF GENES ENCODING POTENTIAL TUMOR IMMUNOGENS . . . . .	62
9.5. SELECTION OF FULL LENGTH CDNA ENCODING POTENTIAL TUMOR IMMUNOGENS . . . . .	66
10. EXAMPLE: INDEPENDENT HUMAN TUMOR CELL LINES DERIVED FROM A NON-TUMORIGENIC, IMMORTALIZED CELL LINE . . . . .	68
25 11. EXAMPLE: GENE EXPRESSION IN FRESH PATIENT BLADDER TUMORS . . . . .	70
12. EXAMPLE: THE USE OF DIFFERENTIALLY EXPRESSED GENE PRODUCTS TO GENERATE CTLs CROSSREACTIVE WITH AUTHENTIC TUMORS . .	72
30 13. EXAMPLE: INDUCTION OF PROTECTIVE IMMUNITY . . . .	74
14. EXAMPLE: CONSTRUCTION AND CHARACTERIZATION OF VACCINIA EXPRESSION VECTORS FOR USE IN VACCINES .	75
14.1. MATERIALS AND METHODS . . . . .	75
35 14.1.1. PLASMID CONSTRUCTION . . . . .	75
14.1.2. GENERATION OF RECOMBINANT VIRUSES .	77

		<u>Page</u>
	14.1.3. GENERATION OF RECOMBINANT VIRUSES BY DIRECT LIGATION . . . .	78
	14.1.4. ANALYSIS OF VIRAL DNA GENOMES . . .	79
	14.1.5. DETERMINATION OF $\beta$ -GLUCURONIDASE ACTIVITY . . . . .	80
5	14.1.6. ANALYSIS OF CYTOXIC T CELL RESPONSE	80
	14.2. RESULTS . . . . .	81
	14.2.1. CONSTRUCTION OF DIRECT LIGATION VECTORS . . . . .	81
	14.2.2. ANALYSIS OF THE STRUCTURE OF THE VIRAL GENOMES . . . . .	83
10	14.2.3. QUANTITATION OF PROMOTER ACTIVITY .	85
	14.2.4. BIOCHEMICAL CHARACTERIZATION OF VIRUS VECTORS . . . . .	86
	14.2.5. CONSTRUCTION OF RECOMBINANT VIRUS BY DIRECT LIGATION . . . . .	87
	14.3. DISCUSSION . . . . .	90
15		
20		
25		
30		
35		



**T CELLS SPECIFIC FOR TARGET ANTIGENS  
AND METHODS AND VACCINES BASED THEREON**

The work reflected in this application was supported, in part, by a grant from the National Institutes of Health, and the Government may have certain rights in the invention.

**1. INTRODUCTION**

The present invention relates to novel methods for the identification of antigens recognized by cytotoxic T cells (CTLs) and specific for human tumors, cancers, and infected cells, and the use of such antigens in immunogenic compositions or vaccines to induce regression of tumors, cancers, or infections in mammals, including humans. The invention encompasses methods for induction and isolation of cytotoxic T cells specific for human tumors, cancers or infected cells, and for improved selection of genes that encode the target antigens recognized by these specific T cells. The invention also relates to differential display methods that improve resolution of, and that reduce the frequency of false positives of DNA fragments that are differentially expressed in tumorous, cancerous, or infected tissues versus normal tissues. The invention further relates to the engineering of recombinant viruses as expression vectors for tumor, cancer, or infected cell-specific antigens.

**2. BACKGROUND OF THE INVENTION**

Current therapies for cancer include surgery, chemotherapy and radiation. The development and use of immunotherapeutic approaches, e.g., tumor targeting using antibody conjugates, "cancer vaccines", etc. is an attractive alternative, but has, to date, met with limited success for a number of reasons. The development of monoclonal antibodies specific for tumor antigens, for example, has proved difficult, in part, because antigens that are recognized by monoclonal antibodies and that are expressed by tumors and

cancer cells are often also expressed by normal, non-cancerous cells. In addition, the expression of membrane antigens targeted by antibodies is frequently modulated to permit growth of tumor variants that do not express those antigens at the cell surface. A cell-mediated immune response may be more effective for eradication of tumors both because of the different array of effector functions that participate in such responses, and because T cell-mediated responses target not only membrane antigens but any tumor-specific intracellular protein that can be processed and presented in association with major histocompatibility molecules. It is, for this reason, much more difficult for a tumor to evade T cell-surveillance by modulating membrane expression.

Immunotherapeutic approaches based on cell-mediated immune responses are likely to be more effective, but antigens that are expressed by tumors and recognized in cell-mediated immune responses are difficult to identify and to produce. Development of an effective treatment for cancer through vaccination and subsequent stimulation of cell-mediated immunity, has remained elusive; the identification of effective antigens to stimulate cell-mediated responses has been successful only in special cases, such as melanoma. In melanoma, the cytotoxic T cells (CTLs) that mediate a cellular immune response against melanoma infiltrate the tumor itself, and such CTLs can be harvested from the tumor and used to screen for reactivity against other melanoma tumors. Isolation of tumor infiltrating lymphocytes has, however, not been a successful strategy to recover cytotoxic T cells specific for most other tumors, in particular the epithelial cell carcinomas that give rise to greater than 80% of human cancer.

To address the problem of identifying effective antigens for use in vaccination, most previous work has focused on screening expression libraries with tumor-specific CTLs to identify potential tumor antigens. There are significant limitations to the existing methods of

identifying effective antigens, including the excessively laborious and inefficient screening process and the considerable difficulty in isolating tumor-specific CTLs for most types of tumors.

5

## 2.1. CANCER VACCINES

The possibility that altered features of a tumor cell are recognized by the immune system as non-self and may induce protective immunity is the basis for attempts to  
10 develop cancer vaccines. Whether or not this is a viable strategy depends on how the features of a transformed cell are altered. Appreciation of the central role of mutation in tumor transformation gave rise to the hypothesis that tumor antigens arise as a result of random mutation in genetically  
15 unstable cells. Although random mutations might prove immunogenic, it would be predicted that these would induce specific immunity unique for each tumor. This would be unfavorable for development of broadly effective tumor vaccines. An alternate hypothesis, however, is that a tumor  
20 antigen may arise as a result of systematic and reproducible tissue specific gene deregulation that is associated with the transformation process. This could give rise to qualitatively or quantitatively different expression of shared antigens in certain types of tumors that might be  
25 suitable targets for immunotherapy. Early results, demonstrating that the immunogenicity of some experimental tumors could be traced to random mutations (De Plaen, et al., 1988, Proc. Natl. Acad. Sci. USA 85: 2274-2278; Srivastava, & Old, 1989, Immunol. Today 9: 78), clearly supported the  
30 first hypothesis. There is, however, no *a priori* reason why random mutation and systematic gene deregulation could not both give rise to new immunogenic expression in tumors. Indeed, more recent studies in both experimental tumors (Sahasrabudhe, et al., 1993, J. Immunology 151:6202-6310;  
35 Torigoe, et al., 1991, J. Immunol. 147:3251) and human melanoma (van Der Bruggen, et al., 1991, Science 254:1643-1647; Brichard, et al., 1993, J. Exp. Med.

178:489-495; Kawakami, et al., 1994, Proc. Natl. Acad. Sci. USA 91:3515-3519; Boel, et al., 1995, Immunity 2:167-175; Van den Eynde, et al., 1995, J. Exp. Med. 182: 689-698) have clearly demonstrated expression of shared tumor antigens  
5 encoded by deregulated normal genes. The identification of  
MAGE-1 and other antigens common to different human melanoma holds great promise for the future development of multiple tumor vaccines.

In spite of the progress in melanoma, shared  
10 antigens recognized by cytotoxic T cells have not been described for other human tumors. The major challenge is technological. The most widespread and to date most successful approach to identify immunogenic molecules uniquely expressed in tumor cells is to screen a cDNA library  
15 with tumor-specific CTLs (cytotoxic T lymphocytes). Application of this strategy has led to identification of several gene families expressed predominantly in human melanoma. Two major limitations of this approach, however, are that (1) screening requires labor intensive transfection  
20 of numerous small pools of recombinant DNA into separate target populations in order to assay T cell stimulation by a minor component of some pool; and (2) with the possible exception of renal cell carcinoma, tumor-specific CTLs have been very difficult to isolate from either tumor infiltrating  
25 lymphocytes (TIL) or PBL of patients with other types of tumors, especially the epithelial cell carcinomas that comprise greater than 80% of human tumors. It appears that there may be tissue specific properties that result in tumor-specific CTLs being sequestered in melanoma.

30 Direct immunization with tumor-specific gene products may be essential to elicit an immune response against some shared tumor antigens. It has been argued that, if a tumor expressed strong antigens, it should have been eradicated prior to clinical manifestation. Perhaps then,  
35 tumors express only weak antigens. Immunologists have long been interested in the issue of what makes an antigen weak or strong. There have been two major hypotheses. Weak antigens

may be poorly processed and fail to be presented effectively to T cells. Alternatively, the number of T cells in the organism with appropriate specificity might be inadequate for a vigorous response (a so-called "hole in the repertoire").

- 5 Elucidation of the complex cellular process whereby antigenic peptides associate with MHC molecules for transport to the cell surface and presentation to T cells has been one of the triumphs of modern immunology. These experiments have clearly established that failure of presentation due to
- 10 processing defects or competition from other peptides could render a particular peptide less immunogenic. In contrast, it has, for technical reasons, been more difficult to establish that the frequency of clonal representation in the T cell repertoire is an important mechanism of low
- 15 responsiveness. Recent studies demonstrating that the relationship between immunodominant and cryptic peptides of a protein antigen change in T cell receptor transgenic mice suggest, however, that the relative frequency of peptide-specific T cells can, indeed, be a determining factor
- 20 in whether a particular peptide is cryptic or dominant in a T cell response. This has encouraging implications for development of vaccines. With present day methods, it would be a complex and difficult undertaking to modify the way in which antigenic peptides of a tumor are processed and
- 25 presented to T cells. The relative frequency of a specific T cell population can, however, be directly and effectively increased by prior vaccination. This could, therefore, be the key manipulation required to render an otherwise cryptic response immunoprotective.
- 30 Another major concern for the development of broadly effective human vaccines is the extreme polymorphism of HLA class I molecules. Class I MHC:cellular peptide complexes are the target antigens for specific CD8+ CTLs. The cellular peptides, derived by degradation of endogenously
- 35 synthesized proteins, are translocated into a pre-Golgi compartment where they bind to class I MHC molecules for transport to the cell surface. The CD8 molecule contributes

to the avidity of the interaction between T cell and target by binding to the  $\alpha 3$  domain of the class I heavy chain. Since all endogenous proteins turn over, peptides derived from any cytoplasmic or nuclear protein may bind to an MHC molecule and be transported for presentation at the cell surface. This allows T cells to survey a much larger representation of cellular proteins than antibodies which are restricted to recognize conformational determinants of only those proteins that are either secreted or integrated at the cell membrane.

The T cell receptor antigen binding site interacts with determinants of both the peptide and the surrounding MHC. T cell specificity must, therefore, be defined in terms of an MHC:peptide complex. The specificity of peptide binding to MHC molecules is very broad and of relatively low affinity in comparison to the antigen binding sites of specific antibodies. Class I-bound peptides are generally 8-10 residues in length and accommodate amino acid side chains of restricted diversity at certain key positions that match pockets in the MHC peptide binding site. These key features of peptides that bind to a particular MHC molecule constitute a peptide binding motif.

Hence, there exists a need for methods to facilitate the induction and isolation of T cells specific for human tumors, cancers and infected cells and for methods to efficiently select the genes that encode the major target antigens recognized by these T cells in the proper MHC-context.

## 2.2. VACCINIA VECTORS

Poxvirus vectors are used extensively as expression vehicles for protein and antigen, e.g. vaccine antigen, expression in eukaryotic cells. Their ease of cloning and propagation in a variety of host cells has led, in particular, to the widespread use of poxvirus vectors for expression of foreign protein and as delivery vehicles for vaccine antigens (Moss, B. 1991, Science 252:1662-7).

Customarily, the foreign DNA is introduced into the poxvirus genome by homologous recombination. The target protein coding sequence is cloned behind a vaccinia promoter flanked by sequences homologous to a non-essential region in the poxvirus and the plasmid intermediate is recombined into the viral genome by homologous recombination. This methodology works efficiently for relatively small inserts tolerated by prokaryotic hosts. The method becomes less viable in cases requiring large inserts as the frequency of homologous recombination is low and decreases with increasing insert size; in cases requiring construction of labor intensive plasmid intermediates such as in expression library production; and, in cases where the propagation of DNA is not tolerated in bacteria. Hence, there is a need for improved methods of introducing large inserts at high frequency, that do not require such labor intensive genetic engineering.

Alternative methods using direct ligation vectors have been developed to efficiently construct chimeric genomes in situations not readily amenable for homologous recombination (Merchlinisky, M. et al., 1992, Virology 190:522-526; Scheifflinger, F. et al., 1992, Proc. Natl. Acad. Sci. USA. 89:9977-9981). These direct ligation protocols have obviated the need for homologous recombination to generate poxvirus chimeric genomes. In such protocols, the DNA from the genome was digested, ligated to insert DNA *in vitro*, and transfected into cells infected with a helper virus (Merchlinisky, M. et al., 1992, Virology 190:522-526, Scheifflinger, F. et al., 1992, Proc. Natl. Acad. Sci. USA 89:9977-9981). In one protocol, the genome was digested at the unique NotI site and a DNA insert containing elements for selection or detection of the chimeric genomes was ligated to the genomic arms (Scheifflinger, F. et al., 1992, Proc. Natl. Acad. Sci. USA. 89:9977-9981). This direct ligation method was described for the insertion of foreign DNA into the vaccinia virus genome (Pfleiderer et al., 1995, J. General Virology 76:2957-2962). Alternatively, the vaccinia WR genome was modified by removing the NotI site in the HindIII

462260 225690

F fragment and reintroducing a NotI site proximal to the thymidine kinase gene such that insertion of a sequence at this locus disrupts the thymidine kinase gene, allowing isolation of chimeric genomes via use of drug selection  
5 (Merchlinisky, M. et al., 1992, Virology 190:522-526).

The direct ligation vector, vNotI/tk allowed one to efficiently clone and propagate DNA inserts at least 26 kilobase pairs in length (Merchlinisky, M. et al., 1992, Virology, 190:522-526). Although, large DNA fragments were  
10 efficiently cloned into the genome, proteins encoded by the DNA insert will only be expressed at the low level corresponding to the thymidine kinase gene, a relatively weakly expressed early class gene in vaccinia. In addition, the DNA will be inserted in both orientations at the NotI  
15 site. Hence, there is a need for more efficient methods of cloning large DNA fragments into the viral genome with accompanying high levels of expression of the protein product encoded by the DNA insert. There also exists a need for improved direct ligation vectors. Such vectors will be more  
20 universally useful for the development of cancer vaccines.

### 3. SUMMARY OF THE INVENTION

The invention relates to methods for the identification of target antigens recognized by CTLs, and the  
25 formulation and use of such antigens in immunogenic compositions or vaccines to induce cell-mediated immunity against target cells, such as tumor cells, that express the target antigens.

Two basic approaches are described for the  
30 identification of target antigens. In one approach, CTLs generated against authentic target cells, such as tumor cells, in animals tolerized to non-target (e.g., non-tumorigenic) cellular counterparts are used to screen expression libraries made from target cell-derived (e.g.,  
35 tumor-derived) DNA, RNA or cDNA to identify clones expressing target antigens. The CTLs generated by the methods described herein are not cross-reactive with normal cells, and thus are



better tools for screening. Improved expression libraries are also described.

In a second approach for identifying target antigens, products of genes differentially expressed in target cells, such as tumor cells, are used to immunize animals to generate HLA-restricted CTLs which are evaluated for activity against authentic target cells. Like the first approach, this second strategy could also be particularly useful for identifying epitopes for many human tumor types where it has not been possible to generate tumor-specific CTLs directly from patients. In addition, it may identify cryptic antigens of the intact tumor cell -- i.e., tumor cell products which can become immunogenic, if the representation of tumor-specific CTLs is first augmented by vaccination with that tumor cell product. Modified methods for differential display that improve resolution and reduce false positives are described.

In accordance with the present invention, the target cell is a cell to which it is desirable to induce a cell-mediated immune response. Examples of target cells in the body include, but are not limited to, tumor cells, malignant cells, transformed cells, cells infected with a virus, fungus, or mycobacteria, or cells subject to any other disease condition which leads to the production of target antigens.

The invention also encompasses the high yield expression of candidate target antigens, and production of recombinant viruses for vaccine formulation.

### 3.1. ABBREVIATIONS

CTLs - cytotoxic T lymphocytes (T cells)  
PBL - peripheral blood lymphocytes  
RDA - Representational Difference Analysis  
TIL - tumor infiltrating lymphocytes

#### 4. DESCRIPTION OF THE FIGURES

**Figure 1.** Nucleotide Sequence of p7.5/tk and pEL/tk. The nucleotide sequence of the promoter and beginning of the thymidine kinase gene for v7.5/tk and vEL/tk.

5

**Figure 2.** Modifications in the nucleotide sequence of the p7.5/tk vaccinia transfer plasmid. Four new vectors, p7.5/ATG0/tk, p7.5/ATG1/tk, p7.5/ATG3/tk, and p7.5/ATG4/tk have been derived as described in the text from the p7.5/tk vaccinia transfer plasmid. Each vector includes unique BamHI, SmaI, PstI, and SalI sites for cloning DNA inserts that employ either their own endogenous translation initiation site (in vector p7.5/ATG0/tk) or make use of a vector translation initiation site in any one of the three possible reading frames (p7.5/ATG1/tk, p7.5/ATG3/tk, and p7.5/ATG4/tk).

10

15

**Figure 3.** Schematic of the Clontech PCR SELECT™ method of Representational Difference Analysis. Adapted from information provided by the manufacturer.

20

**Figure 4.** BCA 39 tumor DNA fragments amplified by PCR following RDA subtraction of B/c.N parental sequences. Nested primers incorporated into the RDA adapters ligated to BCA 39 tumor cell cDNA were employed for sequential PCR amplification of the DNA fragments recovered from RDA. Bands are resolved on a 2% Metaphor agarose gel. One additional low molecular weight band ran off the illustrated gel and was recovered from a shorter electrophoretic run.

25

30

**Figure 5.** Hybridization of an RDA fragment of (A) an IAP *pol* gene or (B) a fragment of the ubiquitously expressed murine G3PDH cDNA to Northern blots of BCA 39 tumor RNA. 15 micrograms of total RNA was transferred from 1% alkaline agarose gel to Genescreen nylon membrane by capillary blot in 10X SSC. The Northern blot was first hybridized to the <sup>32</sup>P

35

labeled RDA clone 1 DNA ( $10^5$  cpm/ml Stark's hybridization buffer), then stripped and hybridized with a 350 bp fragment of G3PDH cDNA.

**5 Figure 6.** RDA clones encoding fragments of IAP gene elements compared with the full length IAP clone MIA14. One or both terminal regions (filled rectangular box) of each RDA clone were sequenced to identify homology to subregions of an IAP element. The extent of overlap was estimated from either the  
**10** fragment size or, where the sequence at both termini of a fragment was determined, the known IAP MIA14 sequence spanning the two termini of that fragment. In one case, clone 2.19, the two measures were not consistent suggesting a deletion in this IAP fragment in BCA 39 tumor cells.

**15**

**Figure 7.** Modified Differential Display of cDNA of parental cell B/c.N and tumors BCA 39, BCA 34, BCA 22, and BCB 13. Fragments of parental and tumor cell cDNA were amplified with one pair of arbitrary decamers, MR\_1 (TAC AAC GAG G) and MR\_5  
**20** (GGA CCA AGT C). For each cell line, first strand cDNA synthesis was separately primed with MR-1 or MR\_5. The two cDNA preparations were then pooled for PCR amplification with both MR\_1 and MR\_5. A number of bands can be identified that are associated with all four tumors but not with the  
**25** immortalized, non-tumorigenic parental cell line.

**Figure 8.** Differential expression in tumor lines of differential display clone 90. RNase protection assay: 300 picograms of clone 90 antisense probe was hybridized with 5  
**30** micrograms total RNA prior to RNase digestion and analysis of protected fragments on 5% denaturing PAGE.

**Figure 9.** Gene isolation in solution. Schematic of a method for selection of longer length cDNA from single strand  
**35** circles rescued from a phagemid library. DNA fragments identified through RDA or Modified Differential Display are employed to select more full length cDNA.

**Figure 10.** Restriction Enzyme Analysis of Virus Genomes Using CHEF Gel. BSC-1 cells were infected at high multiplicity of infection (moi) by vaccinia WR, vEL/tk, v7.5/tk, or vNotI/tk. After 24 hours the cells were harvested and formed into agarose plugs. The plugs were equilibrated in the appropriate restriction enzyme buffer and 1mM PMSF for 16 hours at room temperature, incubated with restriction enzyme buffer, 100ng/ml Bovine Serum Albumin and 50 units NotI or ApaI for two hours at 37°C (NotI) or room temperature (ApaI) and electrophoresed in a 1.0% agarose gel on a Bio-Rad CHEFII apparatus for 15 hours at 6 V/cm with a switching time of 15 seconds. The leftmost sample contains lambda DNA, the second sample contains undigested vaccinia DNA, and the remainder of the samples contain the DNA samples described above each well digested with ApaI or NotI where vEL refers to vEL/tk and v7.5 refers to v7.5/tk. The lower portion of the figure is a schematic map showing the location of the NotI and ApaI sites in each virus.

**Figure 11.** Southern Blot Analysis of Viral Genomes p7.5/tk and pEL/tk. The viruses v7.5/tk and vEL/tk were used to infect a well of a 6 well dish of BSC-1 cells at high multiplicity of infection (moi) and after 48 hours the cells were harvested and the DNA was isolated using DNAzol (Gibco). The final DNA product was resuspended in 50 microliters of TE 8.0 and 2.5 microliters were digested with HindIII, HindIII and ApaI, or HindIII and NotI, electrophoresed through a 1.0% agarose gel, and transferred to Nytran (Schleicher and Schuell) using a Turboblottter (Schleicher and Schuell). The samples were probed with p7.5/tk (Figure 11a) or pEL/tk (Figure 11b) labeled with <sup>32</sup>P using Random Primer DNA Labeling Kit (Bio-Rad) in QuickHyb (Stratagene). The lower portion of the figure denotes a map of the HindIII J fragment with the positions of the HindIII, NotI, and ApaI sites illustrated. The leftmost 0.5 kilobase fragment has electrophoresed off the bottom of the gel.

**Figure 12.** Analysis of v7.5/tk and vEL/tk by PCR. One well of a 6 well dish of BSC-1 cells was infected with v7.5/tk, vEL/tk, vNotI/tk, vpNotI, vNotI/lacZ/tk, or wild type vaccinia WR at high multiplicity of infection (moi) and after 48 hours the cells were harvested, and the DNA was isolated using DNazol (Gibco). The final DNA product was resuspended in 50 microliters of TE (10mM TrisHCl, pH8.0. 1mM EDTA) and used in a PCR with primers MM407 and MM408. The primers are separated by 518 nucleotides in vaccinia WR and yield a fragment containing the N terminus of the thymidine kinase gene. The products were electrophoresed through a 2% agarose gel. The leftmost sample contains phiX 174 HaeIII digestion products; all others contain the PCR product using primers MM407 and MM408 with the DNA sample indicated above the well

**Figure 13.** Promoter strength of recombinant viruses. The units of  $\beta$ -glu activity were determined as described by Miller (10) as adapted for 96-well plates. The  $A_{405}$  values were determined on a microplate reader (Dynatech MR3000) and the  $\beta$ -glu activity was determined by comparison to  $\beta$ -glu (Clontech) standards analyzed in the same assay.

**Figure 14.** Plaque assay on vEL/tk. Ten-fold dilutions of vEL/tk were incubated with Hutk<sup>-</sup> cells (top to bottom) for one hour at 37°C in 1ml of E-MEM (Gibco) with 10% Fetal Bovine Serum for one hour, the media was replaced with 3ml of E-MEM with 5% methyl cellulose (Sigma M-0387), 5% Fetal Bovine Serum and HAT supplement (Gibco), 25 or 125mM bromodeoxyuridine, or no drug, incubated for 48 hours at 37°C, and stained with 0.5% Crystal Violet (Sigma C 0775), 20% ethanol, 7.5% formaldehyde.

## 5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods for the  
35 identification of target antigens recognized by CTLs, and the  
use of such antigens in immunogenic compositions or vaccines

to induce a cell-mediated immune response against cells which express the target antigens.

In one embodiment of the invention, tumor-specific CTLs generated in animals are used to screen expression  
5 libraries generated from tumor cell DNA, RNA or cDNA to identify reactive target antigens. To this end, animals tolerized with a non-tumorigenic human cell line are immunized with tumor cells derived from the non-tumorigenic cell line. The resulting CTLs, which are tumor-specific and  
10 not cross-reactive with normal cells, can be used to screen expression libraries constructed from tumor-cell derived DNA, RNA or cDNA. Clones so identified in the library encode target antigens which are candidates for the immunogenic compositions and vaccines of the invention. Improved and  
15 modified vaccinia virus vectors for efficient construction of such DNA libraries using a "trimolecular recombination" approach are described to improve screening efficiency.

It is a preferred embodiment of the invention to tolerize animals, such as normal or transgenic mice, with  
20 normal human cells prior to immunizing with human tumor cells. Tolerance induction is preferred because the animal's immune response would otherwise be dominated by specificity for a large number of broadly expressed human proteins that are not specifically associated with tumor transformation.  
25 In a particularly preferred embodiment, and to enhance the efficiency of this approach, it is convenient to work with human tumors that are derived from an immortalized, non-tumorigenic human cell line by *in vitro* carcinogenesis or oncogene transformation. This provides a ready source of the  
30 normal control cells for an extended tolerization protocol in both neonatal and adult mice. For example, CTLs generated by this approach (see Section 7 below) can be employed in a selection procedure (such as that described in Section 8 below) to isolate recombinant clones that encode the target  
35 antigens from a tumor cDNA library, for example, such as that constructed in vaccinia virus by tri-molecular recombination (see Section 6 below).

In another embodiment of the invention, the products of genes that are differentially expressed in tumor cells are used to generate HLA-restricted CTLs which are evaluated for activity against authentic tumor cells. It is particularly preferred if methods such as Representational Difference Analysis (RDA) and differential display are employed to identify gene fragments that are differentially expressed in tumor versus normal cells. Conveniently, if it is determined that these gene products are broadly expressed in other related tumors (see, for example, Sections 10 and 11 below), they may be used to select longer clones from the library (see, for example, Section 9.5) which may be tested for the ability to induce a tumor-specific immune response in, for example, human CD8 and HLA transgenic mice (see, for example, Section 12). Gene products which generate tumor-specific cell mediated immunity are also candidates for the immunogenic compositions and vaccines of the invention. Improved methods for differential display are described that enhance screening efficiency by reducing false positives, and enhance the efficiency for isolating full length cDNAs.

The antigens identified using any of the foregoing strategies can be produced in quantity by recombinant DNA methods and formulated with an adjuvant that promotes a cell-mediated immune response. Preferably, the DNA encoding the target antigen is engineered into a recombinant virus that can be used to vaccinate animal hosts, including humans. In this regard, improved direct ligation vaccinia vectors are described that can be used to generate vaccines.

Another therapeutic strategy of the invention is to design vaccines that target a small set of HLA class I molecules which are expressed at elevated frequencies across ethnic populations. Extensive characterization of peptide binding motifs of different human class I MHC molecules has suggested that there are four major subtypes of HLA-A and HLA-B alleles (Sidney, J., et al., 1996, Immunol. Today 17:261-266) such that many peptides will bind to multiple members of a single group. The present invention also

provides methods to target vaccines for patients based on their membership in a class I MHC group. In specific embodiments, class I MHC subtypes A2, A3, B7 and B44 are targeted. Each group has an average representation across 5 ethnic populations of between 40% and 50%. It is estimated that the combination of all four groups (which include 50% to 60% of all known HLA-A and HLA-B alleles) covers 95% of the human population. In a specific embodiment, HLA-A2.1, the most frequently expressed HLA allele in human populations 10 (Caucasian 43%, Black 20%, Chinese 25%) and the dominant member of the A2 subtype, is targeted.

Although the methods of the invention described are used to identify reactive target antigens in tumor cells, the methods may also be used to identify target antigens in other 15 target cells against which it is desirable to induce cell-mediated immunity. For example, the differential immunogenicity methods of the invention can be applied to identify immunogenic molecules of cells infected with virus, fungus or mycobacteria by tolerization of mice with 20 uninfected cells followed by immunization with infected cells at different times after infection. The isolated CTLs can be employed to select recombinants that encode target antigens in a plasmid or viral expression library. An expression library can be constructed with cDNA isolated from the 25 infected cell in a vaccinia virus vector using tri-molecular recombination.

A particular advantage of this approach is that it will identify potential antigens expressed not only by the pathogen but also by the host cell whose gene expression is 30 altered as a result of infection. Since many pathogens elude immune surveillance by frequent reproduction and mutation, it may be of considerable value to develop a vaccine that targets host gene products that are not likely to be subject to mutation.

35 The differential gene expression strategies of the present invention may also be applied to identify immunogenic molecules of cells infected with virus, fungus or



mycobacteria. More stable and/or previously unidentified antigens encoded by genes of either pathogen or host, including those which might remain cryptic without prior specific vaccination, may be identified.

- 5 Pathogens include, but are not limited to:  
viral pathogens, such as human immunodeficiency virus, Epstein Barr virus, hepatitis virus, herpes virus, human papillomavirus, cytomegalovirus, respiratory syncytial virus; fungal pathogens, such as Candida albicans, pneumocystis  
10 carni; and mycobacterial pathogens, such as M. tuberculosis, M. avium.

- The following details and examples mention primarily target antigens in tumor cells. As will be appreciated from the foregoing, the methods of the invention  
15 may be adapted to identify target antigens in other target cells, such as virally infected cells, and may be useful in developing vaccines.

#### 5.1. IDENTIFYING TARGET ANTIGENS FOR USE IN VACCINES

- 20 The subsections below describe two strategies that can be used to identify target antigens or epitopes that are candidates for use in immunogenic formulations or vaccines. The two strategies described herein may be applied to  
25 identify target epitopes which include, but are not limited to, tumor specific, epitopes specific to a cell infected with a virus, fungus or mycobacteria, and/or epitopes specific to an autoimmune disease.

##### 30 5.1.1. INDUCTION OF CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR HUMAN TUMORS AND THEIR USE TO SELECT DNA RECOMBINANTS THAT 35 ENCODE TARGET EPITOPES

- In this embodiment of the invention, cytotoxic T cells specific for human tumors are induced in animals which  
35 have been tolerized with a non-tumorigenic, immortalized normal human cell line that does not express costimulator

activity. These animals are subsequently immunized with costimulator transfected (e.g., B7 transfected) tumor cells derived by *in vitro* mutagenesis or oncogene transformation from that same normal immortalized human cell line. An  
5 alternative source of matched normal and tumor cell pairs that could be employed in this same fashion is to derive normal and tumor cell lines from different tissue samples of the same patient. For purposes of immunization, costimulator activity could also be introduced in these tumor cells by  
10 transfection with murine B7. This immunization regimen gives rise to tumor-specific CTL that are not crossreactive on the homologous normal cells. The primary purpose of inducing tumor-specific CTL is that they can be employed, as described below, to select for clones of recombinant tumor DNA that  
15 encode the target antigen. Such antigens, because they are differentially immunogenic in tumor as compared to normal cells, are candidates for immunogenic formulations or vaccines. Mammals of different species, most commonly diverse strains of inbred mice, can be employed for this  
20 purpose. Whether a particular formulation or vaccine is immunogenic in any particular individual will depend on whether specific peptides derived from that antigen can be processed and presented in association with the particular MHC molecules expressed by that individual. To narrow the  
25 focus of this selection process to antigens from which peptides can be derived that associate with a particular human HLA molecule, it is possible, as described in Section 7, to derive directly HLA restricted CTL from HLA and human CD8 transgenic mice. Alternatively, differentially  
30 immunogenic molecules of the human tumor can be initially identified employing tumor-specific CTL restricted to any animal MHC. Antigens so identified can subsequently be characterized for the ability to be processed and presented in association with different human HLA types by primary *in*  
35 *vitro* stimulation of human peripheral blood lymphocytes (PBL), or, as described in Section 12, by immunization of HLA and human CD8 transgenic mice. The HLA transgene permits

selection of a high affinity, HLA- restricted T cell repertoire in the mouse thymus. In addition, a human CD8 transgene is most preferable because murine CD8 does not interact efficiently with human class I MHC.

- 5           The method to determine differential immunogenicity can be carried out in normal mice if genes encoding mouse MHC molecules are introduced into the human cell lines by transfection (Kriegler, M., 1991, Gene transfer and expression: A laboratory manual, W.H. Freeman and Co., N.Y.). Alternatively, antigens of the human cell lines may be re-presented by murine professional antigen presenting cells *in vivo* (Huang, et al., 1994, Science, 264:961-965) and *in vitro* (Inaba, et al., 1992, J. Exp. Med. 176:1702; Inaba, et al., 1993, J. Exp. Med. 178:479-488). To induce T cell tolerance during re-presentation of human antigens by murine dendritic cells it may be necessary to block costimulator activity with anti-B7.1 and anti-B7.2 antibodies. Specificity of the CTL generated in this way may be determined by comparing lysis of human tumor and normal target cells that have been transfected with HLA class I or that have been infected with HLA class I or that have been infected with HLA class I recombinant vaccinia virus.
- 10  
15  
20

- Since immunogenicity of antigen in any individual depends on whether peptides derived from the antigen can be presented to T cells in association with MHC molecules of that particular individual, it may be separately determined by immunization of human volunteers or of human CD8 and HLA transgenic mice, which human HLA molecules are able to present peptides of any identified antigen. The two issues of immunogenicity and HLA associated presentation can be addressed simultaneously if HLA transgenic mice rather than normal mice are employed in the initial immunization.
- 25  
30

- The construction of transgenic mice is well known in the art and is described, for example, in Manipulating the Mouse Embryo: A laboratory Manual, Hogan, et al., Cold Spring Harbor Press, second edition, 1994. Human CD8 transgenic mice may be constructed by the method of LaFace,
- 35

et al., J. Exp. Med. 182: 1315-25 (1995). Construction of new lines of transgenic mice expressing the human CD8alpha and CD8beta subunits may be made by insertion of the corresponding human cDNA into a human CD2 minigene based  
5 vector for T cell-specific expression in transgenic mice (Zhumabekov, et al., J. Immunol. Methods 185:133-140 (1995)). HLA class I transgenic mice may be constructed by the methods of Chamberlain, et al., Proc. Natl. Acad. Sci. USA 85:7690-7694 (1988) or Bernhard, et al., J. Exp. Med. 168: 1157-62  
10 (1988) or Vitiello, et al., J. Exp. Med. 173: 1007-1015 (1991) or Barra, et al., J. Immunol. 150: 3681-9 (1993).

Construction of additional HLA class I transgenic mice may be achieved by construction of an H-2Kb cassette that includes 2 kb of upstream regulatory region together  
15 with the first two introns previously implicated in gene regulation (Kralova, et al., 1992, EMBO J. 11: 4591-4600). Endogenous translational start sites are eliminated from this region and restriction sites for insertion of HLA cDNA are introduced into the third exon followed by a polyA addition  
20 site. By including an additional 3kb of genomic H-2Kb sequence at the 3' end of this construct, the class I gene can be targeted for homologous recombination at the H-2Kb locus in embryonic stem cells. This has the advantage that the transgene is likely to be expressed at a defined locus  
25 known to be compatible with murine class I expression and that these mice are likely to be deficient for possible competition by H-2Kb expression at the cell membrane. It is believed that this will give relatively reproducible expression of diverse human HLA class I cDNA introduced in  
30 the same construct.

Most preferably, the tumor cell lines are a panel of tumor cell lines that are all derived from a single immortalized, non-tumorigenic cell line. Non-tumorigenic cells are most preferable for inducing tolerance to the large  
35 number of normal human proteins that are also expressed in tumor cells.

Preferably, screening is performed on such a panel of tumor cell lines, independently derived from the same normal cells by diverse carcinogens or oncogene transformation. Screening of such a panel of tumor cell  
5 lines makes it possible to filter out antigenic changes that are carcinogen specific or that may arise by random genetic drift during *in vitro* propagation of a tumor cell line.

The tumor-specific CTLs generated as described above can be used to screen expression libraries prepared  
10 from the target tumor cells in order to identify clones encoding the target epitope. DNA libraries constructed in a viral vector infectious for mammalian cells as described herein can be employed for the efficient selection of specific recombinants by CTLs. Major advantages of these  
15 infectious viral vectors are 1) the ease and efficiency with which recombinants can be introduced and expressed in mammalian cells, and 2) efficient processing and presentation of recombinant gene products in association with MHC  
20 infection (m.o.i.), many target cells will express a single recombinant which is amplified within a few hours during the natural course of infection.

In one embodiment of the invention, a representative DNA library is constructed in vaccinia virus.  
25 Preferably, a tri-molecular recombination method employing modified vaccinia virus vectors and related transfer plasmids is used to construct the representative DNA library in vaccinia virus. This method generates close to 100% recombinant vaccinia virus (see Section 6, Section 6.2 and  
30 6.3).

In a preferred embodiment (see also Section 14, Section 14.1.1), a vaccinia virus transfer plasmid pJ/K, a pUC 13 derived plasmid with a vaccinia virus thymidine kinase gene containing an in-frame Not I site, is further modified  
35 to incorporate one of two strong vaccinia virus promoters, e.g., either a 7.5K vaccinia virus promoter or a strong synthetic early/late (E/L) promoter, followed by Not I and

Apa I restriction sites. The Apa I site is preferably preceded by a strong translational initiation sequence including the ATG codon. This modification is preferably introduced within the vaccinia virus thymidine kinase (*tk*) gene so that it is flanked by regulatory and coding sequences of the viral *tk* gene. Each of the two modifications within the *tk* gene of a plasmid vector may be transferred by homologous recombination in the flanking *tk* sequences into the genome of the Vaccinia Virus WR strain derived vNotI vector to generate two new viral vectors. Importantly, following Not I and Apa I restriction endonuclease digestion of these two viral vectors, two large viral DNA fragments can be isolated each including a separate non-homologous segment of the vaccinia *tk* gene and together comprising all the genes required for assembly of infectious viral particles.

In one embodiment, such modifications are introduced in the Modified Virus Ankara (MVA) strain of vaccinia, which is replication deficient in mammalian cells (Meyer, et al., 1991. J. Gen. Virol. 72:1031-1038).

In a preferred embodiment, the following method is used to enrich for, and select for those cells infected with the recombinant viruses that express the target epitopes of specific cytotoxic T cells. An adherent monolayer of cells is infected with a recombinant viral library, e.g. a vaccinia recombinant viral library, at m.o.i. less than or equal to 1. It is important that these cells do not themselves express the target epitopes recognized by specific CTLs but that these epitopes are represented in the viral library. In addition, for selection by CTLs, the infected cells must express an appropriate MHC molecule that can associate with and present the target peptide to T cells.

After 12 hours infection with recombinant virus, the monolayer is washed to remove any non-adherent cells. CTLs of defined specificity are added for 30 min. During this time, some of the adherent cells infected with a recombinant particle that leads to expression of the target epitope will interact with a specific CTL and undergo a lytic

event. Cells that undergo a lytic event are released from the monolayer and can be harvested in the floating cell population. The above-described protocol is repeated for preferably five or more cycles, to increase the level of  
5 enrichment obtained by this procedure.

**5.1.2. SCREENING CYTOTOXIC LYMPHOCYTES  
GENERATED AGAINST PRODUCTS OF  
GENES DIFFERENTIALLY EXPRESSED  
IN TUMOR CELLS FOR ACTIVITY  
AGAINST AUTHENTIC TUMOR CELLS**

10

In this embodiment of the invention, the products of genes that are differentially expressed in a tumor are used to generate HLA-restricted CTLs (e.g., by immunization of transgenic animals or *in vitro* stimulation of human PBL  
15 with antigen presenting cells that express the appropriate MHC ). The CTLs so generated are assayed for activity against authentic tumor cells in order to identify the differentially expressed gene which encodes the effective target epitope.

20

In essence, this approach to identify tumor-specific antigens is the reverse of the strategy described in the preceding section. Rather than isolating CTLs generated against authentic tumor cells to screen expression libraries of tumor-specific cDNA, the tumor-specific cDNA or gene  
25 products (i.e., the product of genes differentially expressed in tumors) are used to generate CTLs which are then screened using authentic tumor. This strategy is quite advantageously used to identify target epitopes for many human tumor types where it has not been possible to generate tumor-specific CTL  
30 directly from patients. This strategy provides an additional advantage in that cryptic tumor antigens can be identified. Rather than only assaying for what is immunogenic on a tumor cell, this embodiment of the invention allows for the evaluation and assessment of tumor cell products that can  
35 become immunogenic if the representation of tumor-specific T cells is first augmented by vaccination.

Differentially expressed genes derived from the tumor can be identified using standard techniques well known to those skilled in the art (e.g., see Liang & Pardee, 1992, Science 257:967-971, which is incorporated by reference  
5 herein in its entirety). Preferably, the improved differential display methods described in Sections 9.2 and 9.3, infra, may be used to reduce false positives and enhance the efficiency for isolating full length cDNAs corresponding to the identified DNA fragments. Each differentially  
10 expressed gene product is potentially immunogenic, and may be represented as a low-abundance or high abundance transcript.

In order to identify the differentially expressed gene products that might be candidates for tumor immunotherapy, it is necessary to have a means of delivering  
15 the product for immunization in an environment in which T cell responses to peptides associated with human HLA can be induced. To this end, the differentially expressed cDNA is incorporated into an expression vector, preferably a viral vector (such as the vaccinia vectors described herein) so  
20 that quantities of the gene product adequate for immunization are produced. Immunization can be accomplished using the recombinantly expressed gene product formulated in a subunit vaccine (e.g., mixed with a suitable adjuvant that can promote a cell mediated immune response). Preferably a  
25 recombinant viral expression vector, such as vaccinia, can be used to immunize (Bennock & Yewdell, 1990, Current Topics In Microbiol. and Immunol. 163:153-178). Most preferably, transgenic mice are employed which express a human class I MHC molecule, so that HLA-restricted murine cytotoxic T cells  
30 specific for the gene product can be induced and isolated (Shirai, M., et al., 1995, J. Immunol. 154:2733-42; Wentworth et al., 1996, Eur. J. of Immunol. 26:97-101). Alternatively, human PBL are stimulated *in vitro* with antigen presenting cells that express homologous HLA.

35 The significance of HLA compatibility is that T cells recognize peptides that bind to, and are transported to the surface of antigen presenting cells in association with



major histocompatibility molecules. T cells of HLA transgenic mice are, therefore, primed to recognize a specific peptide in association with the expressed human HLA and crossreactivity with human tumor cells depends on  
5 expression of that same tumor peptide in association with the same HLA molecule.

The CTLs induced by the immunization can be tested for cross reactivity on HLA compatible tumors that express the corresponding mRNA. The CTLs can be assayed for their  
10 ability to kill authentic tumor cells *in vitro* or *in vivo*. To this end, assays described in Section 7 can be used, or other similar assays for determining tumor cell specificity and killing which are well known to those skilled in the art.

Using this approach, target epitopes which are  
15 particularly good candidates for tumor immunotherapy in human patients are identified as those which meet the following criteria: (a) the gene is differentially expressed in multiple human tumors; (b) the gene products are immunogenic in association with HLA; and (c) the specific CTLs induced  
20 are cross reactive on human tumor cells.

## 5.2. VACCINE FORMULATIONS

The present invention encompasses the expression of the identified target epitope in either eucaryotic or  
25 procaryotic recombinant expression vectors; and the formulation of the identified epitope as immunogenic and/or antigenic compositions. In accordance with the present invention, the recombinantly expressed target epitope may be expressed, purified and formulated as a subunit vaccine. The  
30 identified target epitope may also be constructed into viral vectors for use in vaccines. In this regard, either a live recombinant viral vaccine, an inactivated recombinant viral vaccine, or a killed recombinant viral vaccine can be formulated.

35

**5.2.1. EXPRESSION OF THE TARGET EPITOPE  
IN PROCARYOTIC AND EUCARYOTIC  
EXPRESSION SYSTEMS**

---

5 The present invention encompasses expression systems, both eucaryotic and procaryotic expression vectors, which may be used to express the identified target epitope. The identified epitope may be expressed in both truncated or full-length forms of the epitope, in particular for the formation of subunit vaccines.

10 The present invention encompasses the expression of nucleotide sequences encoding the identified epitopes and immunologically equivalent fragments. Such immunologically equivalent fragments may be identified by making analogs of the nucleotide sequence encoding the identified epitopes that  
15 are truncated at the 5' and/or 3' ends of the sequence and/or have one or more internal deletions, expressing the analog nucleotide sequences, and determining whether the resulting fragments immunologically are recognized by the epitope specific CTLs and induce a cell-mediated immune response.

20 The invention encompasses the DNA expression vectors that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs expression of the coding sequences and genetically engineered host cells that contain any of the foregoing coding sequences  
25 operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell. As used herein, regulatory elements include but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the  
30 art that drive and regulate expression.

The target epitope gene products or peptide fragments thereof, may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing the epitope gene polypeptides and  
35 peptides of the invention by expressing nucleic acid containing epitope gene sequences are described herein. Methods which are well known to those skilled in the art can

be used to construct expression vectors containing epitope gene product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook et al., 1989, supra, and Ausubel et al., 1989, supra. Alternatively, RNA capable of encoding glycoprotein epitope gene product sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

The invention also encompasses nucleotide sequences that encode peptide fragments of the identified epitope gene products. For example, polypeptides or peptides corresponding to the extracellular domain of the selected epitope may be useful as "soluble" protein which would facilitate secretion, particularly useful in the production of subunit vaccines. The selected epitope gene product or peptide fragments thereof, can be linked to a heterologous epitope that is recognized by a commercially available antibody is also included in the invention. A durable fusion protein may also be engineered; *i.e.*, a fusion protein which has a cleavage site located between the selected epitope sequence and the heterologous protein sequence, so that the selected epitope can be cleaved away from the heterologous moiety. For example, a collagenase cleavage recognition consensus sequence may be engineered between the selected epitope protein or peptide and the heterologous peptide or protein. The epitopic domain can be released from this fusion protein by treatment with collagenase. In a preferred embodiment of the invention, a fusion protein of glutathione-S-transferase and the selected epitope protein may be engineered.

The selected epitope proteins of the present invention for use in vaccine preparations, in particular

subunit vaccine preparations, are substantially pure or homogeneous. The protein is considered substantially pure or homogeneous when at least 60 to 75% of the sample exhibits a single polypeptide sequence. A substantially pure protein  
5 will preferably comprise 60 to 90% of a protein sample, more preferably about 95% and most preferably 99%. Methods which are well known to those skilled in the art can be used to determine protein purity or homogeneity, such as polyacrylamide gel electrophoresis of a sample, followed by  
10 visualizing a single polypeptide band on a staining gel. Higher resolution may be determined using HPLC or other similar methods well known in the art.

The present invention encompasses polypeptides which are typically purified from host cells expressing  
15 recombinant nucleotide sequences encoding these proteins. Such protein purification can be accomplished by a variety of methods well known in the art. In a preferred embodiment, the epitope protein of the present invention is expressed as a fusion protein with glutathione-S-transferase. The  
20 resulting recombinant fusion proteins purified by affinity chromatography and the epitope protein domain is cleaved away from the heterologous moiety resulting in a substantially pure protein sample. Other methods known to those skilled in the art may be used; see for example, the techniques  
25 described in "Methods In Enzymology", 1990, Academic Press, Inc., San Diego, "Protein Purification: Principles and Practice", 1982, Springer-Verlag, New York, which are incorporated by reference herein in their entirety.

#### 30      5.2.1.1. EUCARYOTIC AND PROCARYOTIC EXPRESSION VECTORS

The present invention encompasses expression systems, both eucaryotic and procaryotic expression vectors, which may be used to express the selected epitope. A variety of host-expression vector systems may be utilized to express  
35 the selected target epitope gene of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently

purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the selected epitope gene product of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing selected epitope gene product coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the selected epitope gene product coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the selected epitope gene product coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing selected epitope gene product coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

25

#### 5.2.1.2. HOST CELLS

The present invention encompasses the expression of the selected epitope in animal and insect cell lines. In a preferred embodiment of the present invention, the selected epitope is expressed in a baculovirus vector in an insect cell line to produce an unglycosylated antigen. In another preferred embodiment of the invention, the selected epitope is expressed in a stably transfected mammalian host cell, e.g., T lymphocyte cell line to produce a glycosylated antigen. The selected epitopes which are expressed recombinantly by these cell lines may be formulated as subunit vaccines.

452360 4444444444

A host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g. 5 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be 10 chosen to ensure the correct modification of the foreign protein expressed. To this end, eucaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include 15 but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3 and WI38 cell lines.

For long term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the selected target epitope may be 20 engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and 25 a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells 30 to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines. This method may advantageously be used to engineer cell lines which express the selected epitope 35 gene products. Such cell lines would be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the selected epitope gene product.



epitope can be engineered. A live vaccine may be preferred because multiplication in the host leads to a prolonged stimulus of similar kind and magnitude to that occurring in natural infections, and therefore, confers substantial, long-  
5 lasting immunity. Production of such live recombinant virus vaccine formulations may be accomplished using conventional methods involving propagation of the virus in cell culture or in the allantois of the chick embryo followed by purification.

10 In this regard, a variety of viruses may be genetically engineered to express the selected epitope. For vaccine purposes, it may be required that the recombinant viruses display attenuation characteristics. Current live virus vaccine candidates for use in humans are either cold  
15 adapted, temperature sensitive, or attenuated. The introduction of appropriate mutations (e.g., deletions) into the templates used for transfection may provide the novel viruses with attenuation characteristics. For example, specific multiple missense mutations that are associated with  
20 temperature sensitivity or cold adaptation can be made into deletion mutations and/or multiple mutations can be introduced into individual viral genes. These mutants should be more stable than the cold or temperature sensitive mutants containing single point mutations and reversion frequencies  
25 should be extremely low. Alternatively, recombinant viruses with "suicide" characteristics may be constructed. Such viruses go through only one or a few rounds of replication in the host.

For purposes of the invention, any virus may be  
30 used in accordance with the present invention which: (a) displays an attenuated phenotype or may be engineered to display attenuated characteristics; (b) displays a tropism for mammals, in particular humans, or may be engineered to display such a tropism; and (c) may be engineered to express  
35 the selected target epitope of the present invention.

Vaccinia viral vectors may be used in accordance with the present invention, as large fragments of DNA are



easily cloned into its genome and recombinant attenuated vaccinia variants have been described (Meyer, et al., 1991, J. Gen. Virol. 72:1031-1038). Orthomyxoviruses, including influenza; Paramyxoviruses, including respiratory syncytial virus and Sendai virus; and Rhabdoviruses may be engineered to express mutations which result in attenuated phenotypes (see U.S. Patent Serial No. 5,578,473, issued November 26, 1996). These viral genomes may also be engineered to express foreign nucleotide sequences, such as the selected epitopes of the present invention (see U.S. Patent Serial No. 5,166,057, issued November 24, 1992, incorporated herein by reference in its entirety). Reverse genetic techniques can be applied to manipulate negative and positive strand RNA viral genomes to introduce mutations which result in attenuated phenotypes, as demonstrated in influenza virus, Herpes Simplex virus, cytomegalovirus and Epstein-Barr virus, Sindbis virus and poliovirus (see Palese et al., 1996, Proc. Natl. Acad. Sci. USA 93:11354-11358). These techniques may also be utilized to introduce foreign DNA, i.e., the selected target epitopes, to create recombinant viral vectors to be used as vaccines in accordance with the present invention. In addition, attenuated adenoviruses and retroviruses may be engineered to express the target epitope. Therefore, a wide variety of viruses may be engineered to design the vaccines of the present invention, however, by way of example, and not by limitation, recombinant attenuated vaccinia vectors expressing the selected target epitope for use as vaccines are described herein.

In one embodiment, a recombinant modified vaccinia variant, Modified Virus Ankara (MVA) is used in a vaccine formulation. This modified virus has been passaged for 500 cycles in avian cells and is unable to undergo a full infectious cycle in mammalian cells (Meyer, et al., 1991, J. Gen. Virol. 72:1031-1038). When used as a vaccine, the recombinant virus goes through a single replication cycle and induces a sufficient level of immune response but does not go further in the human host and cause disease. Recombinant

viruses lacking one or more of essential vaccinia virus genes are not able to undergo successive rounds of replication. Such defective viruses can be produced by co-transfecting vaccinia vectors lacking a specific gene(s) required for viral replication into cell lines which permanently express this gene(s). Viruses lacking an essential gene(s) will be replicated in these cell lines but when administered to the human host will not be able to complete a round of replication. Such preparations may transcribe and translate  
5 - in this abortive cycle - a sufficient number of genes to induce an immune response.

Alternatively, larger quantities of the strains can be administered, so that these preparations serve as inactivated (killed) virus, vaccines. For inactivated  
15 vaccines, it is preferred that the heterologous gene product be expressed as a viral component, so that the gene product is associated with the virion. The advantage of such preparations is that they contain native proteins and do not undergo inactivation by treatment with formalin or other  
20 agents used in the manufacturing of killed virus vaccines.

In another embodiment of the invention, inactivated vaccine formulations are prepared using conventional techniques to "kill" the recombinant viruses. Inactivated vaccines are "dead" in the sense that their infectivity has  
25 been destroyed. Ideally, the infectivity of the virus is destroyed without affecting immunogenicity. In order to prepare inactivated vaccines, the recombinant virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by  
30 formaldehyde or  $\beta$ -propiolactone, and pooled. The resulting vaccine is usually inoculated intramuscularly.

Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include but are not limited to  
35 mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols,

polyanions; peptides; oil emulsions; and potentially useful human adjuvants such as BCG and Corynebacterium parvum.

### 5.2.3. METHODS OF TREATMENT AND/OR VACCINATION

5           Since the identified target epitopes of the present invention can be produced in large amounts, the antigen thus produced and purified has use in vaccine preparations. The target epitope may be formulated into a subunit vaccine preparation, or may be engineered into viral vectors and  
10 formulated into vaccine preparations. Alternatively, the DNA encoding the target epitope may be administered directly as a vaccine formulation. The "naked" plasmid DNA once administered to a subject invades cells, is expressed on the surface of the invaded cell and elicits a cellular immune  
15 response, so that T lymphocytes will attack cells displaying the selected epitope. The selected epitope also has utility in diagnostics, e.g., to detect or measure in a sample of body fluid from a subject the presence of tumors and thus to diagnose cancer and tumors and/or to monitor the cellular  
20 immune response of the subject subsequent to vaccination.

          The recombinant viruses of the invention can be used to treat tumor-bearing mammals, including humans, to generate an immune response against the tumor cells. The generation of an adequate and appropriate immune response  
25 leads to tumor regression *in vivo*. Such "vaccines" can be used either alone or in combination with other therapeutic regimens, including but not limited to chemotherapy, radiation therapy, surgery, bone marrow transplantation, etc. for the treatment of tumors. For example, surgical or  
30 radiation techniques could be used to debulk the tumor mass, after which, the vaccine formulations of the invention can be administered to ensure the regression and prevent the progression of remaining tumor masses or micrometastases in the body. Alternatively, administration of the "vaccine" can  
35 precede such surgical, radiation or chemotherapeutic treatment.

Alternatively, the recombinant viruses of the invention can be used to immunize or "vaccinate" tumor-free subjects to prevent tumor formation. With the advent of genetic testing, it is now possible to predict a subject's predisposition for cancers. Such subjects, therefore, may be immunized using a recombinant vaccinia virus expressing an appropriate tumor-associated antigen.

The immunopotency of the epitope vaccine formulations antigen can be determined by monitoring the immune response in test animals following immunization or by use of any immunoassay known in the art. Generation of a cell-mediated immune response may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects.

Suitable preparations of such vaccines include injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, suspension in, liquid prior to injection, may also be prepared. The preparation may also be emulsified, or the polypeptides encapsulated in liposomes. the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.

Examples of adjuvants which may be effective, include, but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine, GM-CSF, QS-21 (investigational drug, Progenics Pharmaceuticals, Inc.), DETOX (investigational drug, Ribic Pharmaceuticals), and BCG.

The effectiveness of an adjuvant may be determined by measuring the induction of the cellular immune response directed against the target epitope.

The vaccines of the invention may be multivalent or  
5 univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution,  
10 suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

15 Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.  
20 Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized epitope of the invention is provided in a first container; a second  
25 container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Use of purified antigens as vaccine preparations can be carried out by standard methods. For example, the  
30 purified protein(s) should be adjusted to an appropriate concentration, formulated with any suitable vaccine adjuvant and packaged for use. Suitable adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic  
35 polyols; polyanions; peptides; oil emulsions; alum, and MDP. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use

in a vaccine formulation. In instances where the recombinant antigen is a hapten, *i.e.*, a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, 5 the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

- 10 Many methods may be used to introduce the vaccine formulations described above into a patient. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, transdermal, epidural, pulmonary, gastric, intestinal, 15 rectal, vaginal, or urethral routes. When the method of treatment uses a live recombinant vaccinia vaccine formulation of the invention, it may be preferable to introduce the formulation via the natural route of infection of the vaccinia virus, *i.e.*, through a mucosal membrane or 20 surface, such as an oral, nasal, gastric, intestinal, rectal, vaginal or urethral route. To induce a CTL response, the mucosal route of administration may be through an oral or nasal membrane. Alternatively, an intramuscular or intraperitoneal route of administration may be used.
- 25 Preferably, a dose of  $10^6$  -  $10^7$  PFU (plaque forming units) of cold adapted recombinant vaccinia virus is given to a human patient.

The precise dose of vaccine preparation to be employed in the formulation will also depend on the route of 30 administration, and the nature of the patient, and should be decided according to the judgment of the practitioner and each patient's circumstances according to standard clinical techniques. An effective immunizing amount is that amount sufficient to produce an immune response to the antigen in 35 the host to which the vaccine preparation is administered.

Where subsequent or booster doses are required, a modified vaccinia virus such as MVA can be selected as the

parental virus used to generate the recombinant.

Alternatively, another virus, e.g., adenovirus, canary pox virus, or a subunit preparation can be used to boost.

Immunization and/or cancer immunotherapy may be accomplished  
5 using a combined immunization regimen, e.g., immunization  
with a recombinant vaccinia viral vaccine of the invention  
and a boost of a recombinant vaccinia viral vaccine. In such  
an embodiment, a strong secondary CD8<sup>+</sup> T cell response is  
induced after priming and boosting with different viruses  
10 expressing the same epitope (for such methods of immunization  
and boosting, see, e.g., Murata et al., Cellular Immunol.  
173:96-107). For example, a patient is first primed with a  
vaccine formulation of the invention comprising a recombinant  
vaccinia virus expressing an epitope, e.g., a selected tumor-  
15 associated antigen or fragment thereof. The patient is then  
boosted, e.g., 21 days later, with a vaccine formulation  
comprising a recombinant virus other than vaccinia expressing  
the same epitope. Such priming followed by boosting induces  
a strong secondary CD8<sup>+</sup> T cell response. Such a priming and  
20 boosting immunization regimen is preferably used to treat a  
patient with a tumor, metastasis or neoplastic growth  
expressing the selected tumor-associated antigen.

In yet another embodiment, the recombinant vaccinia  
viruses can be used as a booster immunization subsequent to a  
25 primary immunization with inactivated tumor cells, a subunit  
vaccine containing the tumor-associated antigen or its  
epitope, or another recombinant viral vaccine, e.g.,  
adenovirus, canary pox virus, or MVA.

In an alternate embodiment, recombinant vaccinia  
30 virus encoding a particular tumor-associated antigen, epitope  
or fragment thereof may be used in adoptive immunotherapeutic  
methods for the activation of T lymphocytes that are  
histocompatible with the patient and specific for the tumor-  
associated antigen (for methods of adoptive immunotherapy,  
35 see, e.g., Rosenberg, U.S. Patent No. 4,690,915, issued  
September 1, 1987; Zarling, et al., U.S. Patent No.  
5,081,029, issued January 14, 1992). Such T lymphocytes may

be isolated from the patient or a histocompatible donor. The T lymphocytes are activated *in vitro* by exposure to the recombinant vaccinia virus of the invention. Activated T lymphocytes are expanded and inoculated into the patient in order to transfer T cell immunity directed against the tumor-associated antigen epitope.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the vaccine formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

The invention will be better understood by reference to the specific embodiments detailed in the examples which follow.

**6. EXAMPLE: TRIMOLECULAR RECOMBINATION  
EMPLOYING MODIFIED VACCINIA VIRUS  
VECTORS TO MAKE EXPRESSION LIBRARIES**

This example describes a tri-molecular recombination method employing modified vaccinia virus vectors and related transfer plasmids that generates close to 100% recombinant vaccinia virus and, for the first time, allows efficient construction of a representative DNA library in vaccinia virus.

**6.1. CONSTRUCTION OF THE VECTORS**

The previously described vaccinia virus transfer plasmid pJ/K, a pUC 13 derived plasmid with a vaccinia virus thymidine kinase gene containing an in-frame Not I site (Merchlsinsky, M. et al., Virology 190:522-526), was further modified to incorporate a strong vaccinia virus promoter followed by Not I and Apa I restriction sites. Two different vectors, p7.5/tk and pEL/tk, included, respectively, either the 7.5K vaccinia virus promoter or a strong synthetic



early/late (E/L) promoter (Fig. 1). The Apa I site was preceded by a strong translational initiation sequence including the ATG codon. This modification was introduced within the vaccinia virus thymidine kinase (tk) gene so that  
5 it was flanked by regulatory and coding sequences of the viral tk gene. The modifications within the tk gene of these two new plasmid vectors were transferred by homologous recombination in the flanking tk sequences into the genome of the Vaccinia Virus WR strain derived vNotI<sup>-</sup> vector to  
10 generate new viral vectors v7.5/tk and vEL/tk. Importantly, following Not I and Apa I restriction endonuclease digestion of these viral vectors, two large viral DNA fragments were isolated each including a separate non-homologous segment of the vaccinia tk gene and together comprising all the genes  
15 required for assembly of infectious viral particles. Further details regarding the construction and characterization of these vectors and their alternative use for direct ligation of DNA fragments in vaccinia virus are described in section 14 infra.

20

#### **6.2. GENERATION OF AN INCREASED FREQUENCY OF VACCINIA VIRUS RECOMBINANTS**

Standard methods for generation of recombinants in vaccinia virus exploit homologous recombination between a  
25 recombinant vaccinia transfer plasmid and the viral genome. Table 1 shows the results of a model experiment in which the frequency of homologous recombination following transfection of a recombinant transfer plasmid into vaccinia virus infected cells was assayed under standard conditions. To  
30 facilitate functional assays, a minigene encoding the immunodominant 257-264 peptide epitope of ovalbumin in association with H-2K<sup>b</sup> was inserted at the Not I site in the transfer plasmid tk gene. As a result of homologous recombination, the disrupted tk gene is substituted for the  
35 wild type viral tk<sup>+</sup> gene in any recombinant virus. This serves as a marker for recombination since tk<sup>-</sup> human 143B cells infected with tk<sup>-</sup> virus are, in contrast to cells

infected with wild type tk+ virus, resistant to the toxic effect of BrdU. Recombinant virus can be scored by the viral pfu on 143B cells cultured in the presence of 125 mM BrdU. The frequency of recombinants derived in this fashion is of 5 the order of 0.1% (Table 1).

10

15

20

25

30

35

Table 1: Generation of Recombinant Vaccinia Virus by Standard Homologous Recombination

Virus*	DNA	Titer without	Titer with	% Recombinant**
		BrdU	BrdU	
5 vaccinia	----	$4.6 \times 10^7$	$3.0 \times 10^3$	0.006
vaccinia	30ng pE/Lova	$3.7 \times 10^7$	$3.2 \times 10^4$	0.086
vaccinia	300ng pE/Lova	$2.7 \times 10^7$	$1.5 \times 10^4$	0.056

10

\* vaccinia virus strain vNot1

\*\* % Recombinant = (Titer with BrdU/Titer without BrdU)x100

This recombination frequency is too low to permit efficient construction of a cDNA library in a vaccinia vector. The following two procedures were used to generate an increased frequency of vaccinia virus recombinants.

(i) One factor limiting the frequency of viral recombinants generated by homologous recombination following transfection of a plasmid transfer vector into vaccinia virus infected cells is that viral infection is highly efficient whereas plasmid DNA transfection is relatively inefficient. As a result many infected cells do not take up recombinant plasmids and are, therefore, capable of producing only wild type virus. In order to reduce this dilution of recombinant efficiency, a mixture of naked viral DNA and recombinant plasmid DNA was transfected into Fowl Pox Virus (FPV) infected mammalian cells. As previously described by others (Scheifflinger, F., et al., 1992, Proc. Natl. Acad. Sci. USA 89:9977-9981), FPV does not replicate in mammalian cells but provides necessary helper functions required for packaging mature vaccinia virus particles in cells transfected with non-infectious naked vaccinia DNA. This modification of the homologous recombination technique alone increased the frequency of viral recombinants approximately 35 fold to 3.5% (Table 2).

Table 2: Generation of Recombinant Vaccinia Virus by Modified Homologous Recombination

5	Virus	DNA	Titer		% Recombinant*
			without BrdU	with BrdU	
	FPV	None	0	0	0
	None	vaccinia WR	0	0	0
10	FPV	vaccinia WR	$8.9 \times 10^6$	$2.0 \times 10^2$	0.002
	FPV	vaccinia WR + pE/Lova (1:1)	$5.3 \times 10^6$	$1.2 \times 10^5$	2.264
15	FPV	vaccinia WR + pE/Lova (1:10)	$8.4 \times 10^5$	$3.0 \times 10^4$	3.571

Table 2: Confluent monolayers of BSC1 cells ( $5 \times 10^5$  cells/well) were infected with moi=1.0 of fowlpox virus strain HP1. Two hours later supernatant was removed, cells were washed 2X with Opti-Mem I media, and transfected using lipofectamine with 600ng vaccinia strain WR genomic DNA either alone, or with 1:1 or 1:10 (vaccinia:plasmid) molar ratios of plasmid pE/Lova. This plasmid contains a fragment of the ovalbumin cDNA, which encodes the SIINFEKL epitope, known to bind with high affinity to the mouse class I MHC molecule K<sup>b</sup>. Expression of this minigene is controlled by a strong, synthetic Early/Late vaccinia promoter. This insert is flanked by vaccinia tk DNA. Three days later cells were harvested, and virus extracted by three cycles of freeze/thaw in dry ice isopropanol/ 37°C water bath. Crude virus stocks were titered by plaque assay on human TK- 143B cells with and without BrdU.

\* %Recombinant = (Titer with BrdU/Titer without BrdU) x 100

35

(ii) A further significant increase in the frequency of viral recombinants was obtained by transfection

of FPV infected cells with a mixture of recombinant plasmids and the two large approximately 80 kilobases and 100 kilobases fragments of vaccinia virus v7.5/tk DNA produced by digestion with Not I and Apa I restriction endonucleases.

- 5 Because the Not I and Apa I sites have been introduced into the *tk* gene, each of these large vaccinia DNA arms includes a fragment of the *tk* gene. Since there is no homology between the two *tk* gene fragments, the only way the two vaccinia arms can be linked is by bridging through the homologous *tk* sequences that flank the inserts in the recombinant transfer plasmid. The results in Table 3 show that >99% of infectious vaccinia virus produced in triply transfected cells is recombinant for a DNA insert as determined by BrdU resistance of infected *tk*- cells.

15

Table 3: Generation of 100% Recombinant Vaccinia Virus using Tri-Molecular Recombination

Virus	DNA	Titer without	Titer with	% Recombinant*
		BrdU	BrdU	
20 FPV	Uncut v7.5/tk	$2.5 \times 10^6$	$6.0 \times 10^3$	0.24
FPV	NotI/ApaI v7.5/tk arms	$2.0 \times 10^2$	0	0
25 FPV	NotI/ApaI v7.5/tk arms	$6.8 \times 10^4$ + 1:1 pE/Lova	$7.4 \times 10^4$	100

- Table 3: Genomic DNA from vaccinia strain V7.5/tk (1.2 micrograms) was digested with ApaI and NotI restriction endonucleases. The digested DNA was divided in half. One of the pools was mixed with a 1:1 (vaccinia:plasmid) molar ratio of pE/Lova. This plasmid contains a fragment of the ovalbumin cDNA, which encodes the SIINFEKL epitope, known to bind with high affinity to the mouse class I MHC molecule K<sup>b</sup>.
- 35 Expression of this minigene is controlled by a strong, synthetic Early/Late vaccinia promoter. This insert is flanked by vaccinia *tk* DNA. DNA was transfected using

lipofectamine into confluent monolayers ( $5 \times 10^5$  cells/well) of BSC1 cells, which had been infected 2 hours previously with  $\text{moi}=1.0$  FPV. One sample was transfected with 600ng untreated genomic V7.5/tk DNA. Three days later cells were  
5 harvested, and the virus was extracted by three cycles of freeze/thaw in dry ice isopropanol/  $37^\circ$  C water bath. Crude viral stocks were plaqued on TK- 143 B cells with and without BrdU selection.

$$* \quad \% \text{Recombinant} = (\text{Titer with BrdU} / \text{Titer without BrdU}) \times 100$$

10

### 6.3. CONSTRUCTION OF A REPRESENTATIVE cDNA LIBRARY IN VACCINIA VIRUS

A cDNA library is constructed in the vaccinia  
15 vector to demonstrate representative expression of known cellular mRNA sequences.

Additional modifications have been introduced into the p7.5/tk transfer plasmid and v7.5/tk viral vector to enhance the efficiency of recombinant expression in infected cells. These include introduction of translation initiation  
20 sites in three different reading frames and of both translational and transcriptional stop signals as well as additional restriction sites for DNA insertion.

First, the HindIII J fragment (vaccinia tk gene) of p7.5/tk was subcloned from this plasmid into the HindIII site  
25 of pBS phagemid (Stratagene) creating pBS.Vtk.

Second, a portion of the original multiple cloning site of pBS.Vtk was removed by digesting the plasmid with SmaI and PstI, treating with Mung Bean Nuclease, and ligating  
30 back to itself, generating pBS.Vtk.MCS-. This treatment removed the unique SmaI, BamHI, SalI, and PstI sites from pBS.Vtk.

Third, the object at this point was to introduce a new multiple cloning site downstream of the 7.5k promoter in pBS.Vtk.MCS-. The new multiple cloning site was generated by  
35 PCR using 4 different upstream primers, and a common downstream primer. Together, these 4 PCR products would

contain either no ATG start codon, or an ATG start codon in each of the three possible reading frames. In addition, each PCR product contains at its 3 prime end, translation stop codons in all three reading frames, and a vaccinia virus transcription double stop signal. These 4 PCR products were ligated separately into the NotI/ ApaI sites of pBS.Vtk.MCS-, generating the 4 vectors, p7.5/ATG0/tk, p7.5/ATG1/tk, p7.5/ATG3/tk, and p7.5/ATG4/tk whose sequence modifications relative to the p7.5/tk vector are shown in Figure 2. Each vector includes unique BamHI, SmaI, PstI, and SalI sites for cloning DNA inserts that employ either their own endogenous translation initiation site (in vector p7.5/ATG0/tk) or make use of a vector translation initiation site in any one of the three possible reading frames (p7.5/ATG1/tk, p7.5/ATG3/tk, and p7.5/ATG4/tk).

In a model experiment cDNA was synthesized from poly-A+ mRNA of a murine tumor cell line (BCA39) and ligated into each of the four modified p7.5/tk transfer plasmids. Twenty micrograms of Not I and Apa I digested v/tk vaccinia virus DNA arms an equal was transfected together with an equimolar mixture of the four recombinant plasmid cDNA libraries into FPV helper virus infected BSC-1 cells for tri-molecular recombination. The virus harvested had a total titer of  $6 \times 10^6$  pfu of which greater than 90% were BrdU resistant.

In order to characterize the size distribution of cDNA inserts in the recombinant vaccinia library, individual isolated plaques were picked using a sterile pasteur pipette and transferred to 1.5ml tubes containing 100  $\mu$ l Phosphate Buffered Saline (PBS). Virus was released from the cells by three cycles of freeze/thaw in dry ice/isopropanol and in a 37° C water bath. Approximately one third of each virus plaque was used to infect one well of a 12 well plate containing tk- human 143B cells in 250  $\mu$ l final volume . At the end of the two hour infection period each well was overlayed with 1 ml DMEM with 2.5% fetal bovine serum (DMEM-2.5) and with BUdR sufficient to bring the final

concentration to 125  $\mu\text{g/ml}$ . Cells were incubated in a  $\text{CO}_2$  incubator at  $37^\circ\text{C}$  for three days. On the third day the cells were harvested, pelleted by centrifugation, and resuspended in 500  $\mu\text{l}$  PBS. Virus was released from the cells by three  
5 cycles of freeze/ thaw as described above. Twenty percent of each virus stock was used to infect a confluent monolayer of BSC-1 cells in a 50mm tissue culture dish in a final volume of 3 ml DMEM-2.5. At the end of the two hour infection period the cells were overlayed with 3 ml of DMEM-2.5. Cells  
10 were incubated in a  $\text{CO}_2$  incubator at  $37^\circ\text{C}$  for three days. On the third day the cells were harvested, pelleted by centrifugation, and resuspended in 300  $\mu\text{l}$  PBS. Virus was released from the cells by three cycles of freeze/ thaw as described above. One hundred microliters of crude virus  
15 stock was transferred to a 1.5 ml tube, an equal volume of melted 2% low melting point agarose was added, and the virus/agarose mixture was transferred into a pulsed field gel sample block. When the agar worms were solidified they were removed from the sample block and cut into three equal  
20 sections. All three sections were transferred to the same 1.5 ml tube, and 250 $\mu\text{l}$  of 0.5M EDTA, 1% Sarkosyl, 0.5mg/ml Proteinase K was added. The worms were incubated in this solution at  $37^\circ\text{C}$  for 24 hours. The worms were washed several times in 500 $\mu\text{l}$  0.5X TBE buffer, and one section of each worm  
25 was transferred to a well of a 1% low melting point agarose gel. After the worms were added the wells were sealed by adding additional melted 1% low melting point agarose. This gel was then electrophoresed in a Bio-Rad pulsed field gel electrophoresis apparatus at 200volts, 8 second pulse times,  
30 in 0.5X TBE for 16 hours. The gel was stained in ethidium bromide, and portions of agarose containing vaccinia genomic DNA were excised from the gel and transferred to a 1.5 ml tube. Vaccinia DNA was purified from the agarose using  $\beta$ -Agarase (Gibco) following the recommendations of the  
35 manufacturer. Purified vaccinia DNA was resuspended in 50  $\mu\text{l}$  ddH<sub>2</sub>O. One microliter of each DNA stock was used as the template for a Polymerase Chain Reaction (PCR) using vaccinia



TK specific primers MM428 and MM430 (which flank the site of insertion) and Klentaq Polymerase (Clontech) following the recommendations of the manufacturer in a 20 $\mu$ l final volume. Reaction conditions included an initial denaturation step at  
5 95°C for 5 minutes, followed by 30 cycles of: 94°C 30 seconds, 55°C 30 seconds, 68°C 3 minutes. Two and a half microliters of each PCR reaction was resolved on a 1% agarose gel, and stained with ethidium bromide. Amplified fragments of diverse sizes were observed. When corrected for flanking  
10 vector sequences amplified in PCR the inserts range in size between 300 and 2500 bp.

The vaccinia virus cDNA library was further characterized in terms of the representation of clones homologous to the murine alpha tubulin sequence. Twenty  
15 separate pools with an average of either 300, 900 or 2,700 viral pfu from the library were amplified by infecting a monolayer of 143B tk- cells in the presence of BrdU. DNA was extracted from each infected culture after three days and assayed for the presence of an alpha tubulin sequence by PCR  
20 with tubulin specific primers. Poisson analysis of the frequency of positive pools indicates a frequency of one alpha tubulin recombinant for every 2000 to 3000 viral pfu. This is not significantly different from the expected frequency of alpha tubulin sequences in this murine tumor  
25 cell line and suggests representative expression of this randomly selected sequence in the vaccinia cDNA library.

#### 6.4. DISCUSSION

The above-described tri-molecular recombination  
30 strategy yields close to 100% viral recombinants. This is a highly significant improvement over current methods for generating viral recombinants by transfection of a plasmid transfer vector into vaccinia virus infected cells. This latter procedure yields viral recombinants at a frequency of  
35 the order of only 0.1%. The high yield of viral recombinants in tri-molecular recombination makes it possible, for the first time, to efficiently construct genomic or cDNA

libraries in a vaccinia virus derived vector. In the first series of experiments a titer of  $6 \times 10^6$  recombinant virus was obtained following transfection with a mix of 20 micrograms of Not I and Apa I digested vaccinia vector arms together  
5 with an equimolar concentration of tumor cell cDNA. This technological advance creates the possibility of new and efficient screening and selection strategies for isolation of specific genomic and cDNA clones.

The tri-molecular recombination method as herein  
10 disclosed may be used with other viruses such as mammalian viruses including vaccinia and herpes viruses. Typically, two viral arms which have no homology are produced. The only way that the viral arms can be linked is by bridging through homologous sequences that flank the insert in a transfer  
15 vector such as a plasmid. When the two viral arms and the transfer vector are present in the same cell the only infectious virus produced is recombinant for a DNA insert in the transfer vector.

Libraries constructed in vaccinia and other  
20 mammalian viruses by the tri-molecular recombination method of the present invention may have similar advantages to those described here for vaccinia virus and its use in identifying target antigens in the CTL screening system of the invention. Similar advantages are expected for DNA libraries constructed  
25 in vaccinia or other mammalian viruses when carrying out more complex assays in eukaryotic cells. Such assays include but are not limited to screening for DNA encoding receptors and ligands of eukaryotic cells.

30        7.    **EXAMPLE:    INDUCTION OF CYTOTOXIC T CELLS  
                              SPECIFIC FOR HUMAN TUMORS IN  
                              HLA AND HUMAN CD8 TRANSGENIC MICE**

In this example, HLA and human CD8 transgenic mice were tolerized with a non-tumorigenic, immortalized normal  
35 human cell line that does not express costimulator activity for murine T cells and were subsequently immunized with B7 (costimulator) transfected tumor cells derived by *in vitro*

mutagenesis or oncogene transformation from that same normal cell line. The HLA transgene permits selection of a high affinity, HLA- restricted T cell repertoire in the mouse thymus. In addition, a human CD8 transgene is required

5 because murine CD8 does not interact efficiently with human class I MHC. Subsequent to immunization with B7 transfected tumor cells, splenic CD8+ T cells are isolated and stimulated again *in vitro* in the absence of costimulation with non-tumorigenic, immortalized human cells. Two pathways of

10 tolerance induction for antigens shared by the tumorigenic and non-tumorigenic cell lines may be activated through these manipulations. As known to those skilled in the art, antigen exposure in very young mice favors tolerance induction by mechanisms that may include both clonal deletion and

15 induction of T cell anergy. Further, restimulation of activated T cells through their antigen-specific receptors in the absence of costimulator activity induces apoptotic elimination of those T cells. This immunization regimen enriched for tumor-specific CTL that did not crossreact with

20 the homologous normal cells.

A series of tumor cell lines were used that were all derived from a single immortalized, non-tumorigenic cell line. The non-tumorigenic cells were used to induce tolerance to the large number of normal human proteins that

25 are also expressed in tumor cells. Availability of a panel of tumors independently derived from the same normal cells by diverse carcinogens or oncogene transformation makes it possible to filter out antigenic changes that are carcinogen specific or that may arise by random genetic drift during *in*

30 *vitro* propagation of a tumor cell line.

Cytotoxic T cells specific for human bladder tumor cell lines were induced and isolated from (HLA-A2/K<sup>b</sup> x human CD8)F<sub>1</sub> hybrid double transgenic mice that had been tolerized to the normal cell line from which the tumors derive.

35 Neonatal mice were injected intraperitoneally with 5 x 10<sup>6</sup> non-tumorigenic SV-HUC. Seven weeks later they were immunized with 5 x 10<sup>6</sup> B7.1 transfected ppT11.B7 tumor cells. ppT11 is

one of several independent tumor cell lines derived from SV-HUC by *in vitro* carcinogenesis (Christian, et al., 1987, Cancer Res. 47: 6066-6073; Pratt, et al., 1992, Cancer Res. 52: 688-695; Bookland, et al., 1992, Cancer Res. 52: 1606-1614). One week after immunization, spleen was removed and a single cell suspension prepared. CD8 positive T cell precursors were enriched on anti-Lyt-2 coated MACS (Magnetic cell sorting beads) as recommended by the manufacturer (Miltenyi Biotech, Sunnyvale, CA).  $1.5 \times 10^6$  CD8 enriched T cells were then restimulated *in vitro* with  $4 \times 10^5$  SV-HUC in 3 ml of RPMI 1640 + 10% fetal bovine serum. The rationale is that any SV-HUC specific T cells that escape neonatal tolerance induction and are activated *in vivo* by stimulation with crossreactive determinants of ppT11.B7, might now be induced to undergo apoptosis by restimulation *in vitro* with costimulator activity negative SV-HUC cells. After 24 hours, T cells are again stimulated with ppT11.B7 in the presence of 2000 Units/ml of recombinant murine IL-6. On day 7 the cycle of SV-HUC stimulation followed 24 hours later by restimulation with ppT11.B7 is repeated. This second round of stimulation with ppT11.B7 is carried out in the presence of 10 nanogram/ml recombinant murine IL-7 and 50 Units/ml recombinant murine IL-2. CTL activity is determined 5 days later by standard chromium release assay from labeled targets SV-HUC, ppT11.B7 and YAC-1, a cell line sensitive to non-specific killing by murine NK cells. The results in Table 4 show that CTL from ppT11.B7 immunized mice that were not previously tolerized to SV-HUC are equally reactive with SV-HUC and ppT11 target cells. In contrast, following neonatal tolerization with SV-HUC, cytolytic T cells at an effector:target ratio of 5:1 are significantly more reactive with ppT11.B7 tumor cells than with SV-HUC. Note that B7 costimulator activity is not required at the effector stage as similar results are obtained with B7 transfected or non-transfected target cells.

Table 4: Tumor-specific response in (HLA-A2/K<sup>b</sup> x human CD8)<sub>F1</sub> hybrid transgenic mice neonatally tolerized with SV-HUC parental cells and then immunized with B7 costimulator transfected ppT11.B7 human bladder tumor cells.

5

Table 4

	Tolerogen:	None		SV-HUC
	Immunogen:	ppT11.B7		ppT11.B7
10				
		Effector:Target ratio		
Target		5:1	10:1	2:1 5:1
SV-HUC		29	68	14 19
15				
ppT11.B7		14	70	17 51
YAC-1		6	6	nd 3

20 nd = not done

The significance of this experimental protocol is that it offers a means of selecting murine, HLA-restricted cytolytic T cells specific for human epithelial tumor cells. As noted previously, it has proved exceedingly difficult to isolate such T cells directly from either patient PBL or tumor infiltrating lymphocytes of tumors other than melanoma and perhaps renal cell carcinoma. In addition, as emphasized in section 5.1.1, this same strategy can be implemented in two stages. Differentially immunogenic molecules of the human tumor can first be identified employing tumor-specific CTL restricted to a variety of different animal MHC. These antigens can, as described in Example 12, subsequently be characterized in human subjects or transgenic mice for the ability to be processed and presented in association with different human HLA types. An advantage of this two stage approach is that numerous different MHC molecules are

available in a variety of inbred strains and these can be employed to capture an equally broad range of tumor-specific immunogenic peptides in the initial screening.

5                    8.    **EXAMPLE:    HIGH-THROUGHPUT STRATEGY  
FOR SELECTION OF DNA RECOMBINANTS  
FROM A LIBRARY THAT ENCODES THE  
TARGET EPITOPES OF SPECIFIC  
CYTOTOXIC T CELLS**

---

10                    In this example, a model system was assayed to determine the level of enrichment that can be obtained through a procedure that selects for DNA recombinants that encode the target epitopes of tumor specific cytotoxic T cells.

15                    8.1.    **METHODS AND RESULTS**

20                    A specific vaccinia recombinant that encodes a well characterized ovalbumin peptide (SIINFEKL) (SEQ ID NO:φφ) was diluted with non-recombinant virus so that it constituted either 0.2%, 0.01%, or 0.001% of viral pfu. This ovalbumin peptide is known to be processed and presented to specific CTL in association with the murine class I MHC molecule H-2K<sup>b</sup>. An adherent monolayer of MC57G cells that express H-2K<sup>b</sup> were infected with this viral mix at m.o.i.=1 (approximately 5 x 10<sup>5</sup> cell/well). MC57G cells do not themselves express ovalbumin peptide, but do express H-2K<sup>b</sup>, which allows them to associate with and present ovalbumin peptide to the T cells.

25                    Following 12 hours of infection with the recombinant vaccinia virus expressing ovalbumin peptide, ovalbumin peptide-specific CTL, derived by repeated *in vitro* stimulation of ovalbumin primed splenic T cells with the immunodominant ovalbumin SIINFEKL peptide, were added for 30 min.

30                    During this time, some of the adherent cells infected with a recombinant particle that leads to expression of the ovalbumin peptide interacted with a specific cytotoxic T cell and underwent a lytic event. Cells that underwent a lytic event were released from the monolayer. After 30 min,

the monolayer was gently washed, and the floating cells and the remaining adherent cells were separately harvested.

Virus extracted from each cell population was titred for the frequency of ovalbumin recombinant viral pfu.

5 Virus extracted from floating cells was then used as input to another enrichment cycle with fresh adherent MC57G cells and ovalbumin peptide-specific CTL. It was observed that, following enrichment of VVova to greater than 10% of total virus, further enrichment of the recombinant virus was  
10 accelerated if the m.o.i. in succeeding cycles was reduced from 1 to 0.1. The results, presented in Table 5, demonstrate marked enrichment of VVova recombinant virus from an initial concentration of 0.2% to 49% or from 0.01% to 39% in 5 enrichment cycles and from 0.001% to 18% in 6 enrichment  
15 cycles. Note that with  $5 \times 10^5$  adherent MC57G cells per well and m.o.i = 1, an initial concentration of 0.001% VVova recombinant virus is equivalent, on average, to seeding only 5 recombinant pfu among  $5 \times 10^5$  wild type vaccinia virus in a single culture well. A very substantial enrichment is  
20 achieved even under these conditions.

Table 5: Multiple Cycles of Enrichment for Vvova

25	Enrichment		% VVova in		
	cycle #		Floating cells*		
			Exp. 1	Exp. 2	Exp. 3
30	moi = 1	0	0.2	0.01	0.001
		1	2.1	0.3	nd
		2	4.7	1.1	nd
		3	9.1	4.9	nd
		4	14.3	17.9	1.4
		5	24.6		3.3
35		6			18.6
	moi=0.1	5	48.8	39.3	

\*     % Vvova = (Titer with BrdU / Titer without BrdU) x 100  
nd = not determined

5

## 8.2. DISCUSSION

The above-described selection method for isolating DNA clones that encode target epitopes of specific cytotoxic T cells from a viral library is far more efficient than existing methods for accomplishing this same goal. Prior to  
10 the present invention, the most widely employed method requires transfection of numerous small pools of recombinant plasmids into separate target populations in order to assay T cell stimulation by a minor component of some pool. Because this requires screening out many negative plasmid pools, it  
15 is a far more labor intensive procedure than the positive selection method described herein. For a given investment of resources, the method described here can detect positive DNA clones that occur at a much lower frequency than would otherwise be possible. The design principle of this strategy  
20 can be directly extended to screening and selection of DNA clones with specific antibodies as well as with CTL.

## 9. EXAMPLE: IDENTIFICATION OF POTENTIAL TUMOR-SPECIFIC ANTIGENS THAT ARE DIFFERENTIALLY EXPRESSED IN TUMORS

25

Identification of genes that are differentially expressed in human tumors, cancers, or infected cells could facilitate development of broadly effective human vaccines. Most methods for identification of differential gene  
30 expression are variations of either subtractive hybridization or the more recently described differential display technique.

Representational difference analysis (RDA) is a subtractive hybridization based method applied to "representations" of total cellular DNA (Lisitsyn, N. and N.,  
35 M. Wigler. 1993. Cloning the differences between two complex genomes. Science 259: 946-951). The differential



display methods of Liang and Pardee (1992, Science 257:967-971) employ an arbitrary 10 nucleotide primer and anchored oligo-dT to PCR amplify an arbitrary subset of fragments from a more complex set of DNA molecules. As  
5 described below (Section 9.2), we have modified differential display to enhance the efficiency with which differentially expressed genes can be identified. In this example we illustrate how application of these methods to a related set of tumors independently derived from a single non-  
10 tumorigenic, immortalized cell line facilitates identification of tumor-specific gene products.

Experiments described by Sahasrabudhe, et al., (1993, J. Immunology 151:6302-6310), focused on a set of murine tumor cell lines, all of which were independently  
15 derived from a single cloned, non-tumorigenic BALB/c embryonic fibroblast cell line. These tumors were of particular interest because they are known to share an immunoprotective antigen. The goal of these experiments was to arrive at a molecular definition of that shared tumor  
20 antigen. The ready availability of tumor cells, as well as the normal cells from which they were derived, was exploited for efficient analysis of differential gene expression and tumor immunogenicity by the methods described below.

The availability of multiple tumors independently  
25 derived from the same normal cells by diverse carcinogens (or oncogene transformation) also makes it possible to filter out antigenic changes that are carcinogen specific or that may arise as a result of random genetic drift during *in vitro* propagation of tumor cells. (See Example 10, where a series  
30 of human tumor cell lines is described that satisfy the requirements of this analysis).

The relationship between the process of transformation and expression of shared tumor rejection antigens was investigated by characterizing the immunological  
35 relationships among a series of murine tumors (BCA 34, BCA 39, BCA 22, and BCB 13) independently derived from B/C-N7.1C.1, a contact inhibited, non-tumorigenic clone of a

continuous fibroblast cell line derived from a BALB/c fetus (Collins, et al., 1982, Nature 299: 167; Lin, et al., 1985, JNCI 74: 1025). Although the proximal cause of tumor transformation may have been a carcinogen induced mutation, 5 this model afforded the opportunity to determine if the process of transformation is also associated with expression of a limited number of shared antigens.

As reported by Sahasrabudhe, et al. (1993, J. Immunology 151: 6302-6310), immunological analysis 10 demonstrates that three of four B/c.N derived tumors confer crossprotective immunity against each other. Concordant with the *in vivo* cross-protection data, cytolytic T cell clones from mice immunized with one of the immunologically related tumors specifically lyse all three immunologically related 15 tumors but, importantly, do not react with the parental B/c.N cells or with the immunologically independent BCB 13 tumor. The observation of immunological cross-reactivity among a group of tumors independently derived from a cloned non-tumorigenic parental cell line strongly suggests that a 20 non-random transformation associated process gives rise to recurrent expression of the same tumor antigen(s). Two methods for analyzing differential gene expression, representational difference analysis (RDA) and modified differential display, were employed to isolate CDNA that 25 might encode the relevant tumor antigen(s).

#### 9.1. REPRESENTATIONAL DIFFERENCE ANALYSIS (RDA)

The PCR SELECT™ variation of RDA is marketed by Clontech (Palo Alto, CA). The following general protocol 30 outlined in the text and in Fig. 3 is a summary of the manufacturer's recommendations. cDNA is synthesized from both a tracer (represented by BCA 39 tumor mRNA) and a driver (represented by parental B/c.N mRNA). "Representations" of both tracer and driver cDNA are created by digestion with 35 RsaI which cuts the four-base recognition sequence GTAC to yield blunt end fragments. Adaptors, which eventually serve as primer sites for PCR, are ligated to the 5' ends of only

the tracer cDNA fragments (Fig. 3). Two aliquots of tracer representation are separately ligated with two different adapters. A series of two hybridizations are carried out. In the first set of hybridizations, each adapter ligated tracer sample is denatured and hybridized with a ten fold excess of the denatured representation of driver cDNA for 8 hours. Under these conditions re-annealing of *all* molecules is incomplete and some of both the high and low copy molecules remain single stranded. Since re-annealing rates are faster for more abundant species, this leads to normalization of the distribution through relative enrichment of low copy number single stranded molecules. The two hybridization reactions with each of the different adapter ligated tracer cDNA representations are then combined *without fractionation or further denaturation* but with addition of more freshly denatured driver in a second hybridization reaction that is allowed to proceed further to completion, approximately 20 hours.

An aliquot of the products from the second hybridization is used as a template for a high stringency PCR reaction, using the known sequences at the 5' ends of the ligated adapters as primers. The key here is that only tumor tracer sequences that 1) remain single stranded through the first hybridization and 2) hybridize to a complementary tracer sequence ligated to the alternate adapter in the second hybridization can be exponentially amplified during PCR. This excludes both tracer and driver species that either remain single stranded or that have hybridized to excess driver (since they have a complementary primer at only one or neither end of the molecule), as well as tracer sequences that hybridize to a molecule with the same adapter (because the adapters are longer than the primers and hybridize to their own complement with higher affinity when it is present on the opposite end of a denatured single stranded molecule - a reaction termed "Suppression PCR" by Clontech). Finally, a second high stringency PCR is performed using nested primers built into the adapters so as

to further reduce background and enrich for differentially expressed sequences. The products of the second PCR are electrophoresed and visualized on an agarose gel. Individual bands are excised and subcloned for further analysis.

5

### **9.2. REPRESENTATIONAL DIFFERENCE ANALYSIS OF GENES THAT ENCODE POTENTIAL TUMOR IMMUNOGENS**

This example describes how the PCR SELECT™ cDNA subtraction method (Clontech Laboratories) was successfully employed to identify a strong candidate for the shared tumor antigen in a set of immunologically related murine tumors.

As shown in Fig. 4, subtraction of a fragmented representation of normal cell cDNA from a similar representation of BCA 39 tumor cDNA resulted in identification of a series of seven clearly distinguishable subtraction products ranging in size from approximately 300 to 2200 base pairs. To confirm that these DNA fragments were indeed differentially expressed, each band was cloned into Bluescript plasmid (Stratagene) and the DNA inserts of at least 5 colonies from each band were analyzed by Northern blot hybridization to RNA of the five different cell lines: the parental cells, the three immunologically crossreactive and the one non-crossreactive tumor cell line. Representative results for clone 3f derived from RDA band 1 are shown in Fig. 5A.

The probe hybridized to at least three transcripts in the BCA 22, 34 and 39 tumor mRNA. Expression of these transcripts is unique to these three immunologically crossreactive tumors. Minimal hybridization is detected with RNA of the parental B/c.N cells or of the non-crossreactive BCB 13 tumor. Similar results were obtained in four Northern blots with independent RNA preparations. The integrity and relative loading of RNA samples was determined by hybridization to a fragment of the mouse G3PDH gene (Fig. 5B).

6460 22553

The sequence of clone 3f was determined and found to be strongly homologous to a portion of the sequence of a murine intracisternal type A particle (IAP element) (Aota, et al., 1987, Gene 56: 1-12). IAPs are endogenous retrovirus-like particles that localize to the cisternae of the endoplasmic reticulum. They are non-infectious because they do not encode functional packaging proteins; the potential env region of the sequence contains many conserved stop codons (Kuff and Lueders, 1988, Advances in Cancer Research 51:183-276). Most IAPs do encode a 73 kDa major gag protein, and a pol polypeptide with some reverse transcriptase properties (Wilson and Kuff, 1972, Proc. Natl. Acad. Sci. USA 69: 1531-1536). Expression of IAP transcripts has been described in various mouse primary tumors (including plasmacytomas, papillomas, carcinomas, mammary tumors, sarcomas, hepatomas) and established mouse tumors and cell lines (including Friend erythroleukemias, myelomonocytic leukemia, T lymphomas, myelomas). Although expression in normal thymus may be elevated, only very low levels of expression are detected in most normal mouse somatic tissues (Kuff and Lueders, 1988, Advances in Cancer Research 51: 183-276).

### 9.3. CHARACTERIZATION OF DIFFERENTIALLY EXPRESSED GENE SEQUENCE FROM RDA

25 Semi-quantitative PCR is a more sensitive test for differential expression than Northern Blot analysis. Clone 3f sequence specific primers were used to amplify full length oligo- dT primed cDNA from both the BCA 39 tumor and the parental cell line. Amplification with mouse tubulin primers was used to normalize the amount of template between the two cell lines. Equal aliquots of each template were amplified through a variable number of PCR cycles. In each case an estimate of the relative template concentration was derived by fitting a line to the portion of the amplification curve in which product increases exponentially with cycle number. The assumption is that in this region yield is a

30  
35

linear function of (initial template concentration)\*(a<sup>n</sup>) where  
a = average amplification per cycle in that PCR region,  
usually between 1.5 and 1.8, and n = cycle number. It was  
determined that expression of the 3f fragment is at least 7  
5 times greater in the BCA39 tumor cDNA relative to the  
parental B/c.N.

Differential expression in tumor RNA was confirmed  
for the inserts of 12 additional clones derived from the six  
other RDA bands. Northern analysis showed the identical  
10 hybridization pattern characteristic of IAP transcripts as  
observed for clone 3f. The sequence of each clone was  
determined and found to be homologous to other regions of the  
IAP genome. A map of the relative position of 10 unique RDA  
clones is shown in Fig. 6. It can be seen that cumulatively  
15 these inserts cover most of the IAP genome.

It is particularly striking that expression of  
these IAP sequences is *shared* among the three immunologically  
crossreactive tumors (BCA 39, BCA 34, and BCA 22) but is  
absent or very low in both the B/c.N parental cells and the  
20 immunologically unrelated BCB 13 tumor. An IAP epitope is,  
therefore, a strong candidate for this shared tumor antigen.  
Experiments are in progress to transfect the different RDA  
clones into antigen negative B/c.N cells which will then be  
tested for sensitization to lysis by tumor-specific CTL.  
25 Transcriptional activation of endogenous retroviral elements  
including IAP may represent a new class of shared tumor  
rejection antigens. It has been reported (de Bergcyck, et  
al., 1994, Eur. J. Immunol. 24:2203-2212) that the tumor  
antigen LEC-A on the murine LEC spontaneous leukemia is also  
30 encoded by the *gag* gene of an IAP element. Recently, a tumor  
rejection antigen of a murine colon tumor, CT26, was found to  
be encoded by another type of endogenous retrovirus, a type C  
particle (Huang, et al., 1996, Proc. Natl. Acad. Sci. USA  
93:9730-9735). Retroviral-like elements are also present in  
35 the human genome: expression of the *pol* gene has been  
detected in human breast (Moyret, et al., 1988, Anticancer  
Res. 8:1279-1283) and colorectal carcinomas (Moshier, et al.,

1986, Biochem. Biophys. Res. Commun. 139:1071-1077), and antibody to the gag gene product has been reported in the sera of patients with human seminoma (Sauter, et al., 1995, J. Virol. 69:414-421) and renal cell carcinoma (Wahlstrom, et al., 1985, Lab. Invest. 53:464-469).

#### **9.4. MODIFIED DIFFERENTIAL DISPLAY OF GENES ENCODING POTENTIAL TUMOR IMMUNOGENS**

In the following example, the differential display methods of Liang and Pardee (1992, Science 257:967-971) were modified to improve resolution of DNA fragments and reduce the frequency of false positives.

The differential display method as originally described by Liang and Pardee (1992, Science 257:967-971) employs an arbitrary 10 nucleotide primer and anchored oligo-dT to PCR amplify an arbitrary subset of fragments from a more complex set of DNA molecules. In principle, differences among the fragments generated from normal and tumor cell lines should reflect differences in gene expression in the two cell types. In practice, this method sometimes works well but often gives rise to numerous false positives. That is, bands which appear to be differentially displayed are, upon further characterization, found not to be differentially expressed. This is presumably due to variable PCR amplification of individual species in complex populations and a relatively high background that can obscure less prominent bands. Since considerable effort is required to establish differential expression, these endemic false positives are costly in terms of efficiency and productivity.

A single arbitrary primer may also be used for differential display, as described by Welch et al. (3,4). Use of single primers does, however, require synthesis of a much larger set of independent primers to achieve the same coverage of a complex cDNA population.

Hence, there exists a need for improved differential display methods that improve resolution of DNA fragments and that reduce the frequency of false positives.

In order to improve the resolution of fragments and reduce the frequency of false positives, a second arbitrary primer was substituted for the anchored oligo-dT employed in PCR amplification. This results in fewer DNA products in  
 5 each PCR reaction so that individual DNA fragments can be more reliably resolved on sequencing gels.

Because each subset of fragments generated in this modified differential display protocol is a smaller representation of total cDNA, more primer pairs are required  
 10 for adequate sampling. Employing the negative binomial distribution, it can be predicted that if 12 independent primers are utilized in all 66 possible primer pair combinations there is a greater than 85% probability that for an average size eukaryotic cDNA at least one primer pair will  
 15 amplify a representative PCR fragment of size  $\geq 70$ bp.

Table 6 lists the sequences of the 12 arbitrary decamers from which primer pairs are selected for modified differential display. The specific primers were chosen on the basis of their sequence diversity, 3' hybridization  
 20 affinity, and minimal pair-wise hybridization.

---

TABLE 6: ARBITRARY PRIMERS FOR MODIFIED DIFFERENTIAL DISPLAY

25	TAC AAC GAG G	MR_1	TCG GTC ACA G	MR_9
	GTC AGA GCA T	MR_2	ATC TGG TAG A	MR_10
	GGA CCA AGT C	MR_5	CTT ATC CAC G	MR_11
	TCA GAC TTC A	MR_7	CAT GTC TCA A	MR_12
	TAC CTA TGG C	MR_8	GAT CAA GTC T	MR_14
30	TGT CAC ATA C	MR_15	CTG ATC CAT G	Ldd1

---

A separate cDNA synthesis reaction with 0.1  $\mu$ g polyA-RNA and Superscript II Reverse Transcriptase (Gibco/BRL) is carried  
 35 out with each primer. Five percent of the cDNA product made with each member of a primer pair is mixed together with that primer pair for amplification in 30 PCR cycles using Klen Taq



Polymerase Mix (Clontech). The PCR primers are used for cDNA synthesis to avoid the 3' bias imposed by oligo-dT primed cDNA synthesis. The relative orientation of the two primers in cDNA is randomized by carrying out a separate synthesis with each primer. These cDNA can be mixed in the same combinations as the primers chosen for PCR amplification. PCR amplified cDNA fragments are resolved on 6% acrylamide gels and dried for autoradiography. Those bands which are differentially displayed in at least 2 tumor samples and not in the parental cells are cut out and rehydrated. An aliquot (1/5) of the DNA recovered is reamplified using the same primer set and the same PCR conditions but without addition of isotope. This second PCR product is resolved on 1% agarose and individual bands are recovered by incubation with  $\beta$  agarase I (Gibco/BRL). Each DNA fragment recovered is cloned by blunt end ligation into the pcDNA3.1/Zeo (+) phagemid vector (Invitrogen). Since it is possible that a single band may include more than one molecular species, at least 4 different transformants with an insert of appropriate size are picked for further characterization. Northern analysis, RNase protection assays and semi-quantitative PCR are employed to confirm differential expression.

In murine tumor cell lines, it was observed that many more differentially expressed gene fragments appear to be identified by differential display than by RDA. In addition, RDA fragments give positive results on Northern blots exposed for only a few hours. In contrast, fragments identified by differential display often do not give a signal on Northern blots even after several days. Differential expression was, in this case, confirmed by Rnase protection and semi-quantitative PCR with sequence specific primers. These observations are consistent with the theoretical expectation that, because of the difficulty of driving hybridization of low abundance cDNA to completion, such sequences will be more readily identified by PCR based differential display than by hybridization based RDA. There may, in addition, be another reason for the greater

sensitivity of modified differential display. It has been reported (Meyuhas and Perry, 1979, Cell 16: 139-148) that mRNA species of low abundance are on average twice the size of smaller, more stable and more abundant mRNA species. It is, therefore, more likely that both members of a pair of arbitrary primers will hybridize to and detect differentially expressed cDNA from the longer (average 4.9 kb) very diverse 80% of mRNA species that are represented by very few copies per cell than from the shorter (average 2 kb) 20% of mRNA species that are more abundantly expressed.

In preliminary experiments, an average of three differentially displayed bands were identified for each pair of primers. With a total of 66 primer pairs generated from all possible combinations of 12 independent primers, approximately 200 gene fragments could be identified. In some cases multiple fragments may derive from the same gene. Fig. 7 shows the pattern of differential display fragments observed with one pair of arbitrary decamers, MR\_1 (TAC AAC GAG G) and MR\_5 (GGA CCA AGT C). A number of bands can be identified that are associated with all four tumors but not with the parental cells. This distribution is unrelated to the immunogenicity of the tumor cells, since only three of the four tumors are immunologically crossreactive. In contrast to the differentially expressed bands identified by RDA, which gave positive results on Northern blots exposed for only a few hours, fragments identified by differential display did not give a signal on Northern blots even after several days. Differential expression of the differential display fragments can, however, be confirmed by RNase protection assays or by semi-quantitative PCR with sequence specific primers. An example is shown in Fig. 8, the results of an RNase protection assay with clone 90 from differential display band 9. This sequence, which has no significant homology to entries in the GenBank database, is expressed in all four tumor lines but not in the parental B/c.N.

As discussed above, we attribute this striking difference in the results of RDA and differential display to

the greater sensitivity of the PCR based modified differential display as compared to the hybridization based RDA method. Based on the pattern of expression in the different tumor and normal cell lines, it appears that the shared tumor antigen detected following direct immunization of mice with syngeneic tumor cells may be encoded by a more abundantly expressed IAP gene. The methods described in this example can be used to determine whether the products of the less abundantly expressed genes identified by modified differential display represent potential cryptic tumor antigens.

#### **9.5. SELECTION OF FULL LENGTH cDNA ENCODING POTENTIAL TUMOR IMMUNOGENS**

This section presents methods for facilitating selection of corresponding full length cDNAs from fragments of differentially expressed genes identified by representational difference analysis or by modified differential display (Fig. 9). A single stranded biotinylated probe is synthesized from isolated cDNA fragments and is used to select the longer cDNA that contain a complementary sequence by solution hybridization to single stranded circles rescued from a phagemid tumor cDNA library. This method is especially well-suited to the use of DNA fragments isolated by the modified differential display method employing two arbitrary primers. The same arbitrary primers employed for PCR amplification of a given fragment in differential display can be modified to generate a single stranded hybridization probe from that fragment. This avoids the need to sequence, select and synthesize a new pair of fragment specific primers for each new fragment of interest.

i) The two oligonucleotides of a pair of PCR primers employed in differential display are modified:  
(biotin-dT)-dT- (biotin-dT) is incorporated at the 5' end of one primer and a phosphate is incorporated at the 5' end of the second primer. These modified primers are incorporated by PCR into the two strands of a differential display

fragment that was selected following the original PCR amplification with the same unmodified arbitrary primers. From this double stranded PCR product, the strand labelled with a 5' phosphate is digested with  $\lambda$  exonuclease to

5 generate a single stranded biotin-labeled probe.

ii) Single stranded (ss) DNA circles are rescued from a phagemid cDNA library using the M13K07 packaging defective phage as helper virus. This library is constructed in the pcDNA3.1/Zeo(+) phagemid (Invitrogen, Carlsbad, CA) with  
10 insertion of (ApaI)oligo-dT primed cDNA between the Apa I and Eco RV restriction sites. A key manipulation to achieve the efficient ligation necessary for construction of a high titer cDNA library is to insure that cDNA inserts are 5' phosphorylated by treating with T4 polynucleotide kinase  
15 prior to ligation. The biotin-labeled single stranded probe generated from the differential display fragment is hybridized in solution to the ssDNA circles of the phagemid library. The biotin-labeled hybridization complexes can then be separated from unrelated ssDNA on streptavidin magnetic  
20 beads and the ss circles eluted for further analysis (Fig. 9).

As a test of this enrichment method, a model plasmid mix was prepared that included 1% of a specific arbitrarily selected recombinant clone, 3f IAP. A  
25 biotinylated ss-probe was prepared from the 3f RDA fragment and used to select single stranded phagemid circles from the 1% plasmid mix. Following elution from streptavidin beads, the single stranded circles were hybridized to a sequence specific oligonucleotide in order to prime synthesis of the  
30 second plasmid strand prior to bacterial transformation. Plasmid DNA was prepared from 63 transformed colonies. 63 of 63 of these plasmid preparations expressed the target 3F IAP insert. This method therefore appears to be very efficient.

The same method appears to work with similar efficiency

35

in the more stringent case of a differential display fragment (B4) representing a previously unidentified sequence that is expressed in all four murine tumors at a concentration approximately 10 fold greater than in the non-tumorigenic parental cells. 5 out of 5 transformants randomly picked following selection of single strand circles with the 200 bp B4 DNA fragment had longer inserts that were positive by PCR with sequence specific primers. This method therefore appears to be very efficient.

10

**10. EXAMPLE: INDEPENDENT HUMAN TUMOR CELL  
LINES DERIVED FROM A NON-TUMORIGENIC,  
IMMORTALIZED CELL LINE**

---

The following example describes a set of human tumors independently derived by different carcinogens or oncogene transformation from the same cloned, non-tumorigenic parental cell line. As in the previous examples of the use of RDA and modified differential display for identification of gene products differentially expressed in murine tumors, the availability of related normal and tumor cell lines has considerable advantages for the molecular and immunological analysis of potential cancer vaccines. This not only provides a readily available source of normal control cells and RNA, but also makes it possible to focus on molecular features that are carcinogen independent and, since they are shared by multiple independent tumors, are unlikely to be the products of random genetic drift during *in vitro* propagation.

A set of human uroepithelial tumors have been derived in the laboratory of Dr. Catherine Reznikoff (University of Wisconsin, Madison) from an SV40 immortalized human uroepithelial cell line, SV-HUC, that is itself contact inhibited, anchorage dependent and non-tumorigenic in nude mice (Christian, et al., 1987, Cancer Res. 47: 6066-6073). A series of independent tumor cell lines were derived by either *ras* transformation (Pratt, et al., 1992, Cancer Res. 52: 688-695) or *in vitro* mutagenesis of SV-HUC with different carcinogens including some that are bladder-specific

(Bookland, et al., 1992, Cancer Res. 52: 1606-1614).

Transformed cells were initially selected on the basis of altered *in vitro* growth requirements and each was shown to be tumorigenic in nude mice. A subset of these tumors is

5 selected that retain the phenotype of transitional cell carcinoma. Table 7 lists the parental cells and the carcinogens employed to derive these 5 tumor lines *in vitro*. A systematic program is undertaken to 1) identify full length cDNA differentially expressed in these tumors and 2) to test  
10 the immunogenicity in HLA and human CD8 transgenic mice of these cDNA products cloned into a vaccinia virus expression vector.

---

15                      TABLE 7: HUMAN UROEPITHELIAL CELL LINES  
Acquired from Dr. Catherine A. Reznikoff, University of Wisconsin Clinical Cancer Center

Parental Line	Immortalization
20 SV-HUC	SV40 immortalized normal bladder epithelial cells
Tumor Line	Carcinogen or Oncogene transformation
MC pT7	3-methylcholanthrene
25 MC ppT11-A3	3-methylcholanthrene followed by 4-aminobiphenyl
MC ppT11-HA2	3-methylcholanthrene followed by N-hydroxy-4-acetylamino-biphenyl
HA-T2	N-hydroxy-4-aminobiphenyl
30 SV-HUC/ <i>ras</i> -T	EJ/ <i>ras</i>

---

Experiments apply both representational difference analysis and modified differential display to identify gene  
35 fragments differentially expressed in the MC ppT11-A3 tumor (ppT11A3) relative to the parental SV-HUC. All differentially expressed fragments are tested by Northern

analysis and RNase protection assay for parallel expression in mRNA of the other tumor cell lines. Only those DNA clones expressed in at least 3 of the 5 SV-HUC derived tumor cell lines are selected for further characterization.

- 5            Similar analysis of tumor-specific gene products can be carried out with tumors derived from SV40 large T or HPV E6 or E7 immortalized cell lines representative of other human tissues. Published examples include: prostatic epithelium (Parda et al., 1993, The Prostate 23: 91-98, ),  
10 mammary epithelium (Band et al., 1990, Cancer Res. 50: 7351-73-57), and bronchial epithelium (Gerwin et al., 1992, Proc. Natl. Acad. Sci. USA 89: 2759-2763; Klein-Szanto et al., 1992, Proc. Natl. Acad. Sci. USA 89: 6693-6697).

15            11.    EXAMPLE: GENE EXPRESSION IN FRESH PATIENT BLADDER TUMORS

             The above-described methods for identification of differentially expressed genes require that both tumor and normal control cell mRNA be readily available. The preceding  
20 section focuses on tumors derived *in vitro* from immortalized cell lines, from which mRNA may be readily obtained in large quantities.

- In spite of the advantages of working with *in vitro*-derived tumors from which mRNA may be readily obtained,  
25 it is necessary to address the possibility that some transformation-associated gene expression might be missed or, conversely, that some differential gene expression detected might not be transformation related. Although the normal control is contact inhibited, anchorage dependent and  
30 non-tumorigenic, it is likely that it has undergone some pre-neoplastic event that is the basis for continuous growth *in vitro*. Perhaps a greater concern is that extraneous gene expression associated with *in vitro* proliferation might be identified. Two strategies to exclude such events are  
35 employed. First, genes are analyzed that are expressed in at least 3 of the 5 bladder tumor lines but that are not expressed in the *in vitro* adapted parental cells. This will

a) filter out any systematic gene expression selected by *in vitro* growth, since this should be shared by the normal parental cells; and b) identify any alterations in gene expression that are carcinogen specific or that may arise as a result of random genetic drift during *in vitro* propagation, since it is not expected that these would be shared by multiple independent tumors derived by diverse carcinogens (or oncogene transformation). Second, and most important, only those differentially expressed genes that can also be shown to be expressed in multiple samples of fresh patient tumor material are selected for further characterization.

Patient tumor material together with normal bladder epithelium is cryopreserved following surgery. In comparison to some other carcinomas, normal tissue control is readily available from bladder cancer patients. Total RNA is extracted from frozen samples by the acid guanidinium isothiocyanate method (Lee and Costlow, 1987, Methods in Enzymology 152:633-648). Following Dnase I treatment, polyA mRNA is fractionated on oligo dT beads and gene expression is analyzed by Northern blot, RNase protection assay, and semi-quantitative RT/PCR. For each differentially expressed gene fragment identified in the *in vitro* tumor lines, expression of the gene is characterized in a panel of 20 patient tumors and normal tissue controls. This sample size permits the estimation of the proportion of patients expressing the gene with a standard error no greater than 0.11% ( $SE = \sqrt{p(1-p)/n}$  where  $p$ =true proportion and  $n$ =sample size. SE is maximal for  $p=0.5$ , at that proportion, 10/20 patients,  $SE = \pm 0.11$ ; for any other value of  $p$ , SE is smaller.) Expression of some of these genes may be correlated in the different tumor samples. This is useful because it creates the possibility of multiple T cell epitopes that could associate with different human MHC molecules.

The expression pattern is also determined, in other normal adult and fetal tissues, of any gene that is differentially expressed in bladder tumors relative to normal



bladder epithelium. Total RNA or first strand cDNA prepared from over 30 different human normal adult or fetal tissues (Discovery Line™ RNA and Gene Pool™ cDNA, Invitrogen, Carlsbad, CA) is used. Expression in fetal but not normal adult tissue is particularly interesting and does not preclude consideration as an immunotherapeutic reagent. Expression of intermediate abundance species are determined by Northern analysis. Low abundance species are quantitated by RNase protection assay and semi-quantitative PCR. Those sequences that are recurrently expressed in tumors derived from multiple patients and which have the lowest relative expression in normal tissue are selected for further characterization as potential tumor-specific antigens.

15           **12.   EXAMPLE:   THE USE OF DIFFERENTIALLY  
EXPRESSED GENE PRODUCTS TO GENERATE CTLs  
CROSSREACTIVE WITH AUTHENTIC TUMORS**

---

To identify differentially expressed gene products that might be candidates for tumor immunotherapy, it is necessary to have a means of delivering the product for immunization in an environment in which T cell responses to peptides associated with human HLA can be induced. T cells induced by immunogenic products could then be tested for crossreactivity on HLA compatible tumors that express the corresponding mRNA. This example describes the use of HLA and human CD8 transgenic mice for induction of T cell responses to peptides associated with human HLA. If all these conditions are met: 1) the gene is differentially expressed in multiple human tumors but not normal tissue counterparts; 2) gene products are immunogenic in association with HLA; and 3) the specific T cells induced are crossreactive on human tumor cells, then this would constitute key preliminary data preparative to initiation of clinical vaccine trials.

To determine whether the products of differentially expressed genes are immunogenic, groups of three (HLA-A2.1 x huCD8)F<sub>1</sub> transgenic mice are immunized intravenously with 5 x

10<sup>6</sup> pfu of each specific recombinant vaccinia virus (Bennink and Yewdell, 1990, Current Topics in Microbiol. and Immunol. 163: 153-178). After at least two weeks, mice are sacrificed and CD8+ splenic T cells are enriched on anti-CD8 coated  
5 magnetic beads. CD8+ cytolytic precursors are restimulated *in vitro* with parental SV-HUC cells that are transfected with the recombinant differentially expressed gene previously isolated in the pCDNA3.1/Zeo(+) plasmid expression vector (Section 9.3). Substitution of the plasmid recombinant in  
10 place of the vaccinia vector for restimulation *in vitro* is necessary to avoid a large vaccinia vector specific response. After five days *in vitro* culture, cytolytic activity is determined by <sup>51</sup>Cr release from SV-HUC target cells transfected with either the specific recombinant plasmid or a  
15 control ovalbumin gene recombinant.

This same cytolytic assay can be readily applied to determine whether the relevant CTL epitope is also presented by HLA compatible tumor cells that express the corresponding mRNA. If T cells are induced in (HLA-A2.1 x huCD8)F<sub>1</sub>  
20 transgenic mice, HLA compatible targets include tumor cells that either express native HLA-A2.1 or that have been transfected with HLA-A2.1. The immunogenicity of differentially expressed gene products is established and it is determined whether there is a crossreaction with human  
25 tumor cells. This finding, together with the demonstration that the same mRNA is expressed in multiple samples of fresh patient tumors but not normal tissues (Section 11), is required prior to initiation of a clinical vaccine trial.

An important consideration for vaccine development  
30 is the extensive polymorphism of human class I HLA. As discussed above, an appealing strategy is to target four major HLA subtypes, A2, A3, B7 and B44, that provide broad coverage across ethnic populations. Many peptides bind to multiple members of a single subtype. If several CTL  
35 epitopes are identified for each subtype, then this can greatly facilitate formulation of a broadly effective vaccine.

### 13. EXAMPLE: INDUCTION OF PROTECTIVE IMMUNITY

It is desirable, especially in the case of cryptic tumor antigens encoded by low abundance mRNA, to determine whether a T cell response to differentially expressed gene products confers protective tumor immunity. Since a number of differentially expressed genes have been identified in the murine tumor model described above, such experiments are carried out in mice.

It has previously been reported for this murine tumor model (Sahasrabudhe, et al., 1993, J. Immunology 151: 6302-6310) that three of four independently derived tumors are immunologically crossreactive. Many of the differentially displayed bands identified in these tumors are, in contrast, present in all four tumors. It is, therefore, unlikely that the genes from which these fragments derive are immunologically dominant in animals inoculated with these tumors.

If it is shown that direct immunization with a recombinant differentially expressed gene does, nevertheless, confer protective immunity, then this provides compelling evidence for the efficacy of vaccination with a cryptic tumor antigen.

Groups of 5 mice of the BALB/c strain syngeneic to the murine tumors are immunized with each vaccinia virus recombinant for a full length cDNA differentially expressed in all four murine tumor lines but not the parental B/c.N cells (Fig. 7). Each group of mice is assayed for induction of protective immunity by challenge with a tumorigenic inoculum of  $1 \times 10^6$  BCA 39 tumor cells (Sahasrabudhe, et al., 1993, J. Immunology 151:6302-6310). To determine whether protective immunity correlates with relative quantitative expression, independent gene products are tested that represent different levels of differential expression as determined by semi-quantitative PCR.

35

**14. EXAMPLE: CONSTRUCTION AND  
CHARACTERIZATION OF VACCINIA  
EXPRESSION VECTORS FOR USE IN VACCINES**

This example describes the construction and  
5 characterization of a new set of direct ligation vectors  
designed to be universally applicable for the generation of  
chimeric vaccinia genomes. The aim was to modify the genome  
of vNotI/tk so as to acquire direct ligation vectors which  
are more universally useful. First, the insertion site was  
10 changed by placing the sites for two unique restriction  
enzymes at the beginning of the thymidine kinase gene. This  
allows one to fix the orientation of the insert DNA and  
eliminates the production of contaminating wild type genomes  
after religation of viral arms. Second, in order to generate  
15 a direct ligation vector which would express high levels of  
protein, the thymidine kinase gene was preceded by a strong  
constitutive vaccinia virus promoter.

These new ligation vectors contain a pair of unique  
restriction sites, NotI and ApaI, to eliminate religation of  
20 poxvirus arms and fix the orientation of the insert DNA  
behind strongly expressing constitutive vaccinia promoters.  
The insertion cassette has been placed at the beginning of  
the thymidine kinase gene in vaccinia to utilize drug  
selection in the isolation of recombinants.

25

**14.1. MATERIALS AND METHODS**

**14.1.1. PLASMID CONSTRUCTION**

Pairs of oligonucleotides were constructed which,  
when annealed, contained the 7.5k gene promoter  
30 (MM436:GGCCAAAATTGAAAACTAGATCTATTTATTGCACGCGCCGCCATGGGCCC  
(SEQ ID NO.: $\phi\phi$ ) and MM437:  
GGCCGGGCCCATGGCGGCCGCGTGCAATAAATAGATCTAGTTTTTCAATTTTT (SEQ ID  
NO.:  $\phi\phi$ )), or the synthetic EL promoter  
(MM438:GGCCAAAATTGAAATTTTTATTTTTTTTTTTTGAATATAAAGCGGCCGCCAT  
35 GGGCCC (SEQ ID NO.: $\phi\phi$ ) and MM439:  
GGCCGGGCCCATGGCGGCCGCTTATATTCACAAAAAATAAATTTCAATTTTT  
(SEQ ID NO.: $\phi\phi$ )) and restriction sites for NotI and ApaI.

The double-stranded oligonucleotides were annealed by ramping from 94° C to 20° C over two hours and ligated into the NotI site present in pJNotI/tk, a plasmid containing the HindIII J fragment from vNotI/tk, resulting in plasmids p7.5/tk and  
5 pEL/tk.

A Polymerase Chain Reaction (PCR) was performed on pBI221, a plasmid containing the *E.coli gusA* gene encoding for  $\beta$ -glucuronidase ( $\beta$ -glu), using primers MM440 (GGGAAAGGGGCGGCCCATGTTACGTCCTGTAGAAACC) (SEQ ID NO.: $\phi\phi$ ) and  
10 MM441 (GGGAAAGGGGCGCCCTCATTGTTTGCCTCCCTGCTG) (SEQ ID NO.: $\phi\phi$ ), or MM440 and MM442 (GGGAAAGGGGCGGCCCTCATTGTTTGCCTCCCTGCTG) (SEQ ID NO.: $\phi\phi$ ), and the resulting fragment was cloned into pCRII (TA cloning kit, Invitrogen). The plasmids were excised with NotI (MM440/MM442 product) and cloned into  
15 pJNot/tk digested with NotI yielding pJNot/tk-GUS, or excised with NotI and ApaI (MM440/MM441 product), and inserted into pEL/tk and p7.5/tk previously digested with ApaI and NotI yielding p7.5/tk-GUS and pEL/tk-GUS.

Pairs of oligonucleotides were constructed which,  
20 when annealed, contained the 7.5k gene promoter and the nucleotide sequence encoding for a cytotoxic T-cell epitope for ovalbumin (11) (SIINFELK; SEQ ID NO: $\phi\phi$ ) (75ova: GGCCAAAAATTGAAAACTAGATCTATTTATTGCACCATGAGTATAATCAACTTTGAAAA ACTGTAGTGA (SEQ ID NO.: $\phi\phi$ ) and 75ovarv:  
25 GGCCTCACTACAGTTTTTCAAAGTTGATTAATACTCATGGTGCAATAAATAGATCTAGTT TTTCAATTTTT (SEQ ID NO.: $\phi\phi$ )) or the EL promoter and the peptide SIINFELK (SEQ ID NO:  $\phi\phi$ ) (ELova: GGCCAAAAATTGAAATTTTATTTTTTTTTTTTGGGAATATAAACCATGAGTATAATCAACT TTGAAAACTGTAGTGA (SEQ ID NO.: $\phi\phi$ ) and ELovarv:  
30 GGCCTCACTACAGTTTTTCAAAGTTGATTATACTCATGGTTTATATTCCAAAAAATAAATAATTTCAATTTTT (SEQ ID NO.: $\phi\phi$ )). The double-stranded oligonucleotides were annealed by ramping from 94° C to 20° C over two hours and ligated into the NotI site present in pJNotI/tk, a plasmid containing the HindIII J fragment from  
35 vNotI/tk resulting in plasmids p7.5/tk-ova and pEL/tk-ova.

#### 14.1.2. GENERATION OF RECOMBINANT VIRUSES

Cells and viruses were maintained and manipulated as described by Earl, et al. (1991, *In Ausubel, et al., (eds.), Current Protocols in Molecular Biology*. Greene Publishing Associates/Wiley Interscience, New York).

Recombinant viruses were made using homologous recombination by infecting CV-1 cells at a multiplicity of infection (moi) of 0.05 and two hours later transfecting DNA into the infected cells using lipofectamine (Life Technologies Incorporated) as suggested by the manufacturer. After 72 hours the cells were harvested and isolated plaques were selected by passage in Hutk cells in the presence of bromodeoxyuridine (Earl, et al., 1991, *In Ausubel, et al. (eds.), Current Protocols in Molecular Biology*. Greene Publishing Associates/Wiley Interscience, New York) or HAT supplemented media (Weir, et al., 1982, *Proc. Nat. Acad. Sci. USA*, 79:1210-1214).

Vaccinia virus was generated from viral DNA by rescue with fowlpox virus (Scheifflinger, et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:9977-9981). Vaccinia virus was isolated from infected HeLa cells by banding and sedimentation in sucrose (Earl, et al., 1991, *In Ausubel, et al. (eds.), Current Protocols in Molecular Biology*. Greene Publishing Associates/Wiley Interscience, New York). The purified virions were treated with Proteinase K (Boehringer Mannheim) and gently extracted with buffer saturated phenol, phenol:chloroform (50:50), and chloroform before precipitation with 2.5 volumes of ethanol in 0.3M sodium acetate and resuspended in TE (10mM TrisHCl, pH8.0. 1mM EDTA (Earl, et al., 1991, *In Ausubel, et al. (eds.), Current Protocols in Molecular Biology*. Greene Publishing Associates/Wiley Interscience, New York). Confluent wells of BSC-1 cells from a 12 well dish were infected with fowlpox virus and after a two hour incubation at 37° C were transfected with 0.6 µg full length vaccinia DNA using Lipofectamine (Life Technologies Incorporated) as suggested by the manufacturer. After 24, 48, and 72 hours the cells

were harvested, lysed by three freeze-thaw cycles and screened by plaque assay on BSC-1 cells (Earl, et al., 1991, *In Ausubel, et al., (eds.), Current Protocols in Molecular Biology*. Greene Publishing Associates/Wiley Interscience, 5 New York).

#### 14.1.3. GENERATION OF RECOMBINANT VIRUSES BY DIRECT LIGATION

The 1.1 kB Eco RI/ Eco RV restriction endonuclease fragment containing ovalbumin from pHbeta -Ova-neo (Pulaski, et al., 1996, *Proc. Natl. Acad. Sci. USA*, 93:3669-3674) was inserted into the EcoRI and EcoRV sites of pBluescript KS+ (Stratagene), generating pBS.ova. The DNA product from a Polymerase Chain Reaction (PCR) on pBS.ova using primers VV0LZ5 (GCAGGTGCGGCCGCGTGGATCCCCGGGCTGCAGG) (SEQ ID NO.:  $\phi\phi$ ) and VVTLZ3 (GTACCGGGCCCACAAAAACAAAATTAGTTAGTTAGGCCCCCCTCGA) (SEQ ID NO.:  $\phi\phi$ ) was digested with ApaI and NotI (Life Technologies, Inc.), gel purified from low melting point agarose (Bio-Rad) using beta Agarase (Life Technologies, Inc.) following the recommendations of the manufacturer, and cloned into pBluescript KS+ that had been digested with NotI and ApaI, generating pBS.VVova. A DNA fragment encoding ovalbumin was excised from pBS.VVova by digestion of this plasmid with ApaI and NotI and purified after electrophoresis through a low melting point agarose gel using beta Agarase. One microgram of purified vEL/tk DNA was digested with ApaI and NotI and centrifuged through a Centricon 100 concentrator (Amicon) to remove the small intervening fragment. The vEL/tk DNA arms and the DNA fragment encoding ovalbumin were ligated overnight at room temperature, at a 4:1 (insert: virus) molar ratio, in 30 microliters with 5 units T4 DNA Ligase. The ligation product was transfected using lipofectamine (Life Technologies, Inc.) into a well of confluent BSC-1 cells from a 12 well plate two hours after infection with fowlpox virus at 1 pfu/cell. Three days later the cells were harvested and isolated plaques were selected by passage in Hutk- cells in

the presence of bromodeoxyuridine (Earl, et al., 1991 *In Ausubel, et al. (eds.), Current Protocols in Molecular Biology*. Greene Publishing Associates/Wiley Interscience, New York).

5

#### 14.1.4. ANALYSIS OF VIRAL DNA GENOMES

BSC-1 cells were infected at high multiplicity of infection (moi) by vaccinia WR, vEL/tk, v7.5/tk, or vNotI/tk. After 24 hours the cells were harvested and resuspended in  
10 Cell Suspension Buffer (Bio-Rad Genomic DNA Plug Kit) at  $1 \times 10^7$  cells/ml. An equal volume of 2% CleanCut agarose (Bio-Rad) preincubated at 50° C was added and the cell suspension was formed into 100  $\mu$ l plugs. After hardening at 4° C the plugs were treated as previously described to digest protein  
15 (Merchinsky, et al., 1989. *J. Virol.* 63:1595-1603). The plugs were equilibrated in the appropriate restriction enzyme buffer and 1mM PMSF for 16 hours at room temperature, incubated with restriction enzyme buffer, 100ng/ml Bovine Serum Albumin and 50 units NotI or ApaI for two hours at 37°  
20 C (NotI) or room temperature (ApaI) prior to electrophoresis.

One well of a 6 well dish of BSC-1 was infected with v7.5/tk or vEL/tk at high multiplicity of infection (moi) and after 48 hours the cells were harvested, pelleted by low speed centrifugation, rinsed with Phosphate-Buffered  
25 Saline (PBS), and the DNA was isolated using DNAzol (Gibco). The final DNA product was resuspended in 50 microliters of TE (10mM TrisHCl, pH8.0. 1mM EDTA) and 2.5 microliters were digested with HindIII, HindIII and ApaI, or HindIII and NotI, electrophoresed through a 1.0% agarose gel, and transferred  
30 to Nytran (Schleicher and Schuell) using a Turboblottter (Schleicher and Schuell). The samples were probed with p7.5/tk (Figure 11a) or pEL/tk (Figure 11b) labeled with  $^{32}$ P using Random Primer DNA Labeling Kit (Bio-Rad) in QuickHyb (Stratagene) and visualized on Kodak XAR film.

35 One well of a 6 well dish of BSC-1 cells was infected with v7.5/tk, vEL/tk, vNotI/tk, vpNotI, vNotI/lacZ/tk, or wild type vaccinia WR at high multiplicity



of infection (moi) and after 48 hours the cells were harvested, pelleted by low speed centrifugation, rinsed with Phosphate-Buffered Saline (PBS), and the DNA was isolated using DNazol (Gibco). The final DNA product was resuspended  
5 in 50 microliters of TE (10mM TrisHCl, pH8.0. 1mM EDTA) and used in a PCR (30 cycles, 1 minute 94° C, 2 minutes 55° C, 3 minutes 72° C, MJ Research PTC-100) with primers MM407 (GGTCCCTATTGTTACAGATGGAAGGGT) (SEQ ID NO.:  $\phi\phi$ ) and MM408 (CCTTCGTTTGCCATACGCTCACAG) (SEQ ID NO.:  $\phi\phi$ ). The nucleotide  
10 sequence was determined by <sup>35</sup>S sequencing using Sequenase Version 2.0 DNA Sequencing Kit (Amersham), and visualized after electrophoresis through 8% denaturing polyacrylamide gels by exposure to Bio-Max film (Kodak).

15           **14.1.5. DETERMINATION OF  $\beta$ -GLUCURONIDASE ACTIVITY**

A well of BSC-1 cells from a 12 well plate was infected at an moi of 1 with vNotI/tk-GUS, v7.5/tk-GUS and vEL/tk-GUS, the cells were harvested 20 hours post infection, resuspended in 0.5ml PBS, and disrupted by three cycles of  
20 freeze-thawing. The extract was clarified by a short microfuge spin (one minute, 14,000 rpm) and the supernatant was analyzed for  $\beta$ -glu units as described by Miller, 1972, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY as adapted for 96-well  
25 plates. The A<sub>405</sub> values were determined on a microplate reader (Dynatech MR3000) and the  $\beta$ -glu activity was determined by comparison to  $\beta$ -glu (Clontech) standards analyzed in the same assay.

30           **14.1.6. ANALYSIS OF CYTOXIC T CELL RESPONSE**

Confluent monolayers of MC57G cells in wells of a 6 well plate were infected at an moi of 1 with vEL/tk, v7.5/tk-ova, vEL/tk-ova, vEL/tk-ovaFL clone 1, and vEL/tk-ovaFL clone 2 (vEL/tk-ovaFL are virus clones of full length ovalbumin  
35 generated by direct ligation). At 16 hours post infection cells were harvested, labeled with 100 microcuries <sup>51</sup>Chromium (Dupont) for 1 hour at 37° C, and 10<sup>4</sup> cells were added to

45269 226690  
wells of a 96 well round bottom plate in quadruplicate. A sample of uninfected MC57G cells incubated with 1 micromolar purified ova 257-264 peptide was also incubated with <sup>51</sup>Cr as a positive control and untreated MC57G cells were used as a negative control. T cells specific for ova 257-264 were added to target cells at ratios of 2:1 and 10:1. Cells were incubated at 37° C for 4 hours, supernatants were harvested, and <sup>51</sup>Cr release determined. Spontaneous release was derived by incubating target cells with media alone and maximal release was determined by incubating target cells with 5% Triton X 100. Percentage of specific lysis was calculated using the formula: % specific lysis= ((experimental release-spontaneous release) / (maximal release-spontaneous release)) X 100. In each case the mean of quadruplicate wells was used in the above formula.

#### 14.2. RESULTS

##### 14.2.1. CONSTRUCTION OF DIRECT LIGATION VECTORS

The vaccinia WR genome is approximately 190 kilobases in length and rich in A and T residues. The complete sequence of the vaccinia WR genome was provided by P. Earl of the Bernard Moss laboratory (Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD). A restriction enzyme search of the complete sequence of the vaccinia WR genome using MacVector (IBI) revealed a lack of restriction sites for ApaI, AscI, Bsp120I, FseI, RsrII, SfiI, SrfI and SgfI. The ready availability of highly active and pure preparations of the enzyme as well as the generation of a staggered end upon digestion led us to choose to use ApaI as the second site in conjunction with the NotI site already present in vNot/tk.

Vaccinia virus based expression vectors are most useful when the foreign protein is expressed constitutively. The expression of foreign proteins during the early stage of viral replication is essential for cytotoxic T cell response (Bennick, et al. 1990, Topics Microbiol. Immunol. 163:153-184) and high levels of total protein expression have been

observed using promoters active during the late stage of viral replication. We decided to incorporate the promoters corresponding to the constitutively expressed 7.5k gene (Mackett, et al., 1984, J. Virology, 49:857-864) and a  
5 constitutively expressed synthetic promoter EL noted for high level expression.

A useful feature of vNotI/tk that must be retained in any new vector is the ability to discriminate for recombinant viral genomes using selection against an active  
10 thymidine kinase gene. The introduction of the ApaI site within the coding sequence for the tk gene necessitates an increase in the total number of amino acids in order to accommodate the restriction enzyme site. A comparison of the amino acid sequence for thymidine kinase genes from a variety  
15 of animal and viral species showed the region of greatest heterogeneity was at the N terminus of the protein, suggesting that this region of the protein could tolerate a modest increase in the number of amino acids.

The recombination-independent cloning vectors were  
20 constructed by making plasmid intermediates containing the modified thymidine kinase (tk) gene and replacing the tk sequence in the vNotI/tk genome by homologous recombination. Two sets of oligonucleotide pairs were constructed which, when annealed, contained the promoter for the 7.5k gene or  
25 the synthetic EL sequence and restriction sites for NotI and ApaI. The modified thymidine kinase genes were constructed by annealing the double-stranded oligonucleotides and ligating the product into the NotI site present at the beginning of the thymidine kinase gene in pJNotI/tk, a  
30 plasmid containing the HindIII J fragment from vNotI/tk. The oligonucleotide pairs annealed to and eliminated the NotI site in pJNotI/tk generating a new NotI site closely followed by an ApaI site after the promoter and flanking the nucleotides coding for the initial methionine in the  
35 thymidine kinase gene resulting in plasmids p7.5/tk and pEL/tk (Figure 1). The acquisition of the ApaI site was verified by restriction enzyme analysis of plasmid DNA and

the nucleotide sequence of the thymidine kinase gene promoter was determined and found to be as depicted in Figure 1.

The recombinant viruses derived from p7.5/tk and pEL/tk were isolated using a strategy relying on positive  
5 drug selection in the presence of HAT (hypoxanthine, aminopterin, thymidine) (Weir, et al., 1982, Proc. Nat. Acad. Sci. USA 79:1210-1214). The viruses vpNotI, a virus that contains a copy of pBR322 inserted at the NotI site of vNotI/tk (Merchlinisky, et al., 1992, Virology 190:522-526),  
10 and vNotI/lacZ/tk, a virus with a copy of the lacZ gene interrupting the thymidine kinase in vNotI (Merchlinisky, et al., 1992, Virology. 190:522-526) are thymidine kinase negative (tk<sup>-</sup>) viruses that are identical to vNotI/tk except for the inserted DNA at the beginning of the tk gene. The  
15 plasmids p7.5/tk and pEL/tk were recombined with vpNotI and vNotI/lacZ/tk helper viruses in CV-1 cells and the infected monolayers were harvested and passaged in the presence of HAT media on Hutk<sup>-</sup> cells. Individual plaques were passaged and isolated an additional three rounds on Hutk<sup>-</sup> cells before  
20 expansion and analysis.

#### **14.2.2. ANALYSIS OF THE STRUCTURE OF THE VIRAL GENOMES**

The growth of v7.5/tk and vEL/tk virus in HAT supplemented media implies these viruses, in contrast to  
25 vpNot and vNot/lacZ/tk, contain an active thymidine kinase (tk) gene. However, an active tk gene could arise from multiple crossovers which delete the 7.5k or EL promoter sequences, generating a virus with the normal tk promoter. The v7.5/tk and vEL/tk genomes should contain a unique site  
30 for both NotI and ApaI within the HindIII J fragment. The genomic structure of the isolated virus stocks was analyzed by restriction enzyme digestion of DNA in agarose plugs derived from virus infected cells using NotI or ApaI and electrophoresis of the products through 1% agarose (Figure  
35 10). Uncut vaccinia WR (lane 2) migrates at a size of 190 kilobase pairs as compared to multimers of bacteriophage lambda (lane 1). After digestion with NotI vaccinia WR is

cleaved into two fragments approximately 150 and 40 kilobase pairs in length (7th lane from left) whereas the vNot/tk, vEL/tk, and v7.5/tk were cleaved into fragments of about 110 and 80 kilobase pairs. When the same samples were digested with ApaI, only one fragment the size of the uncut genome was observed for both vaccinia WR and vNot/tk while vEL/tk and v7.5/tk gave the same sized fragments observed after digestion with NotI. Therefore, both v7.5/tk and vEL/tk contain a unique site for both ApaI and NotI, the sites are at the same locus as the NotI site in vNot/tk, and the sites are in a more central location in the genome than the HindIII F fragment which contains the NotI site in vaccinia WR. The background of cellular DNA fragments was more pronounced in the ApaI digestion, which has a six base pair recognition site, than for the NotI digest.

The genomes for vEL/tk and v7.5/tk were analyzed by Southern blotting to confirm the location of the ApaI and NotI sites in the HindIII J fragment as shown in Figure 11. The filters were hybridized to <sup>32</sup>P labeled HindIII J fragment derived from the p7.5/tk or pEL/tk. The genomes for v7.5/tk and vEL/tk have an ApaI site that does not appear in vNotI/tk (compare lanes 7 and 8 to lane 5 in each blot) whereas digestion with NotI and HindIII yield a set of fragments of equivalent size. The 0.5 kilobase HindIII/NotI or HindIII/ApaI fragment from the left hand side of HindIII J produced from NotI or ApaI digestion has electrophoresed off the bottom of the agarose gel.

The definitive characterization of the promoter sequence utilized products of Polymerase Chain Reaction (PCR). A pair of primers flanking the beginning of the tk gene were used to generate a DNA fragment from the viruses vNotI/tk, v7.5/tk, or vEL/tk and their cognate plasmids as shown in Figure 12. The PCR products for v7.5/tk and vEL/tk are the same size as those observed for the plasmids used to generate the viruses (p7.5/tk and pEL/tk) and larger than those seen for vaccinia WR and vNotI/tk. The PCR fragments were cloned into the plasmid pCRII, the nucleotide sequence

was determined and shown to match the sequence displayed in Figure 1.

#### 14.2.3. QUANTITATION OF PROMOTER ACTIVITY

5           The v7.5/tk and vEL/tk vectors have been designed to constitutively express elevated levels of insert protein in comparison to vNotI/tk. The level of RNA synthesis was measured by infecting confluent BSC-1 cells in the presence and absence of cytosine arabinoside (AraC) at an moi of 5,  
10 harvesting the cells, isolating the RNA using Trizol (Life Technologies) and analyzing the level of thymidine kinase RNA synthesis by primer extension (Weir, et al., 1990, Nucleic Acids Research 16:10267-10282). Incubation with AraC blocks viral DNA replication, allowing one to identify the class of  
15 viral promoter.

          The early class of viral promoters are active prior to DNA replication and will be unaffected by AraC in the infection. Late promoters are only expressed after the onset of DNA replication and their activity is abrogated in the  
20 presence of AraC. Perusal of the products on a denaturing polyacrylamide gel demonstrated that significantly more (estimated to be at least ten fold) tk RNA primer extension products were synthesized in vEL/tk infections as compared to vNot/tk. In cells infected with vNot/tk a single RNA start  
25 site insensitive to AraC incubation was observed whereas in vEL/tk infections two distinct start sites, one resistant to AraC and corresponding to the appropriate early start site (Davison, et al., 1989, J. Mol. Biol. 210:749-769), and one species sensitive to AraC and corresponding to the  
30 appropriate late start of RNA (Davison, et al. 1989, J. Mol. Biol. 210:771-784) were observed (data not shown). The pattern of RNA species derived from infection with v7.5/tk was similar to that observed for vEL/tk with the absolute levels of RNA expression intermediate to that observed for  
35 vEL/tk and vNot/tk.

          In order to verify the levels of expression for genes inserted into the viral vectors the *E.coli gusA* gene

encoding for  $\beta$ -glucuronidase ( $\beta$ -glu) was cloned into vNotI/tk, v7.5/tk and vEL/tk viral vectors and the relative promoter strength was measured. The DNA fragment encoding for the  $\beta$ -glu gene was inserted into plasmids containing each promoter generating pJNot/tk-GUS, p7.5/tk-GUS and pEL/tk-GUS. The correct orientation of the insert  $\beta$ -glu gene in pJNot/tk was verified by restriction enzyme analysis. The plasmids were recombined with vNotI/tk and the recombinant viruses identified by staining with X-glu (Carroll, et al., 1995, BioTechniques 19:352-355), passaged for three rounds through Hutk<sup>-</sup> cells, and expanded to generate the viral stocks vNotI/tk-GUS, v7.5/tk-GUS and vEL/tk-GUS. The structures of the recombinant viruses were verified by Southern blot analysis.

The level of expression of  $\beta$ -glu by vNotI/tk-GUS, v7.5/tk-GUS and vEL/tk-GUS was measured from infected confluent monolayers of BSC-1 cells in the presence or absence of AraC (Figure 13). The level of  $\beta$ -glu expression for the v7.5/tk-GUS and vEL/tk was much higher than that observed for vNotI/tk-GUS and highest (approximately twenty fold higher) in the vEL/tk-GUS. Expression of  $\beta$ -glu was observed for all three viruses in the presence of cytosine arabinoside, indicating that each promoter is a member of the early class of viral promoters. The level of  $\beta$ -glu in vNotI/tk-GUS was unchanged in the presence or absence of AraC indicating that this promoter is only active early during infection, whereas the  $\beta$ -glu levels in v7.5/tk-GUS and vEL/tk-GUS were lower in the presence of AraC, indicating these promoters are active both early and late times during infection.

#### 14.2.4. BIOCHEMICAL CHARACTERIZATION OF VIRUS VECTORS

The v7.5/tk and vEL/tk vectors were initially isolated by growth in the presence of HAT supplemented media and are designed to contain an active tk gene to allow selection for viruses with inserts via passage in Hutk<sup>-</sup> cells in the presence of bromodeoxyuridine (Earl, et al., 1991, In





primate cell lines, can be used at higher moi than vaccinia. In order to determine if fowlpox can serve as an efficient helper virus a series of wells from a 12 well plate containing BSC-1 cells were infected with varying mois of fowlpox and transfected with full length vaccinia WR DNA, the cells were harvested after 24, 48, or 72 hours and the virus titer was determined as shown in Table 8. Transfection of DNA sans fowlpox or fowlpox infection alone resulted in no plaques. The level of rescued vaccinia increased with later harvest and was proportional to the moi of the fowlpox infection.

TABLE 8			
	FPV moi	Day harvested	Titer (pfu x 10 <sup>-3</sup> )
15	0.2	1	0
		2	0.12
		3	300
	0.5	1	0
		2	0.23
		3	500
20	1.0	1	0
		2	1.1
		3	700

**Table 8.** Packaging of vaccinia DNA by fowlpox virus. Vaccinia DNA was transfected into BSC-1 cells infected with fowlpox virus using lipofectamine as described in Section 14.1 (Materials and Methods). The cells were harvested at 1, 2, or 3 days post transfection, lysed by freeze-thaw cycles and assayed for infectious virus by plaque assay on BSC-1 cells.

A 1.1 kilobase pair fragment of the ovalbumin cDNA (Pulaski, et al., 1996, Proc. Natl. Acad. Sci. USA 93:3669-3674) was used as a model insert to study the generation of functional recombinant virus by direct ligation. The ovalbumin insert was modified as described in the Materials

and Methods to include a NotI site at its 5' end, translation stop codons, a vaccinia transcription stop signal and an ApaI site at its 3' end. This insert was digested with NotI and ApaI and ligated with purified vEL/tk DNA arms that had been  
5 digested with NotI and ApaI. The ligation mix was transfected into fowlpox infected BSC-1 cells, cells were harvested, and after three days the cell extract was passaged on Hutk<sup>-</sup> cells in the presence or absence of 125mM bromodeoxyuridine. The titer obtained without drug selection  
10 was  $2.7 \times 10^3$  pfu and with drug selection  $2.8 \times 10^3$  pfu. Individual plaques were picked from Hutk<sup>-</sup> cells in the presence and absence of bromodeoxyuridine and tested for the presence of the ovalbumin insert by dot blot hybridization with an ovalbumin cDNA probe. All 15 plaques picked in the  
15 presence of bromodeoxyuridine, and all 10 plaques picked in its absence contained the ovalbumin insert. These viruses were named vEL/tk-ovaFL. Two individual clones were expanded further and tested for the ability to sensitize host cells to lysis by ova 257-264 specific cytotoxic T lymphocytes (CTL).  
20 The results of this experiment are shown in Table 9. As controls, vaccinia recombinant for an ova 257-264 minigene, v7.5/tk-ova and vEL/tk- ova, were generated by homologous recombination. These ova peptide recombinant viruses were tested in concert with the vEL/tk-ovaFL clones for the  
25 ability to sensitize host cells to lysis by ova specific CTL. As shown in Table 9, infection with either full length or minigene ovalbumin vaccinia recombinants was as efficient as pulsing with 1  $\mu$ M purified OVA 257-264 peptide for sensitization of target cells to lysis by OVA-specific CTL.

30

35

		Effector:Target Ratio	
MC57G cells:		2:1	10:1
		(Percent Specific Lysis)	
5	Untreated	-1.3	-1.3
	ova257-264 peptide, 1 $\mu$ M	54	83
	vEL/tk	-0.5	0
	v7.5/tk-ova Homologous Recombination	50	78
	vEL/tk-ova Homologous Recombination	47	71
10	vEL/tk-ovaFL Direct Ligation Clone 1	48	70
	vEL/tk-ovaFL Direct Ligation Clone 2	46	74

**Table 9.** CML assay on recombinant vaccinia virus infected cells. Virally infected MC57G cells were generated as described in Section 14.1 (Materials and Methods). One sample of MC57G cells was treated with ova257-264 peptide (1 $\mu$ M), another sample of cells was left untreated. Cells were incubated with two different ratios of ova specific cytotoxic T lymphocytes for 4 hours at 37° C and percent specific lysis was determined as described in Section 14.1 (Materials and Methods).

### 14.3. DISCUSSION

Large DNA viruses are particularly useful expression vectors for the study of cellular processes as they can express many different proteins in their native form in a variety of cell lines. In addition, gene products expressed in recombinant vaccinia virus have been shown to be efficiently processed and presented in association with MHC class I for stimulation of cytotoxic T cells. The gene of interest is normally cloned in a plasmid under the control of a promoter flanked by sequences homologous to a non-essential region in the virus and the cassette is introduced into the genome via homologous recombination. A panoply of vectors for expression, selection and detection have been devised to accommodate a variety of cloning and expression strategies.

However, homologous recombination is an ineffective means of making a recombinant virus in situations requiring the generation of complex libraries or when the insert DNA is large. An alternative strategy for the construction of  
5 recombinant genomes relying on direct ligation of viral DNA "arms" to an insert and the subsequent rescue of infectious virus has been explored for the genomes of poxvirus (Merchlinsky, et al., 1992, Virology 190:522-526; Pfleiderer, et al., 1995, J. General Virology 76:2957-2962; Scheifflinger,  
10 et al., 1992, Proc. Natl. Acad. Sci. USA 89:9977-9981), herpesvirus (Rixon, et al., 1990, J. General Virology 71:2931-2939) and baculovirus (Ernst, et al., 1994, Nucleic Acids Research 22:2855-2856).

Poxviruses are ubiquitous vectors for studies in  
15 eukaryotic cells as they are easily constructed and engineered to express foreign proteins at high levels. The wide host range of the virus allows one to faithfully express proteins in a variety of cell types. Direct cloning strategies have been devised to extend the scope of  
20 applications for poxvirus viral chimeras in which the recombinant genomes are constructed *in vitro* by direct ligation of DNA fragments to vaccinia "arms" and transfection of the DNA mixture into cells infected with a helper virus (Merchlinsky, et al., 1992, Virology 190:522-526;  
25 Scheifflinger, et al., 1992, Proc. Natl. Acad. Sci. USA 89:9977-9981). This approach has been used for high level expression of foreign proteins (Pfleiderer, et al., 1995, J. Gen. Virology 76:2957-2962) and to efficiently clone fragments as large as 26 kilobases in length (Merchlinsky, et  
30 al., 1992, Virology 190:522-526).

Vaccinia virus DNA is not infectious as the virus cannot utilize cellular transcriptional machinery and relies on its own proteins for the synthesis of viral RNA. Previously, temperature sensitive conditional lethal  
35 (Merchlinsky, et al., 1992, Virology 190:522-526) or non-homologous poxvirus fowlpox (Scheifflinger, et al., 1992, Proc. Natl. Acad. Sci. USA 89:9977-9981) have been utilized

as helper virus for packaging. An ideal helper virus will efficiently generate infectious virus but not replicate in the host cell or recombine with the vaccinia DNA products. Fowlpox virus has the properties of an ideal helper virus as  
5 it is used at 37° C, will not revert to a highly replicating strain, and, since it does not recombine with vaccinia DNA or productively infect primate cell lines, can be used at relatively high moi.

The utility of the vaccinia based direct ligation  
10 vector vNotI/tk, has been described by Merchlinsky, et al. (1992, Virology 190:522-526). This genome lacks the NotI site normally present in the HindIII F fragment and contains a unique NotI site at the beginning of the thymidine kinase gene in frame with the coding sequence. This allows the  
15 insertion of DNA fragments into the NotI site and the identification of recombinant genomes by drug selection. The vNotI/tk vector can be used to efficiently clone large DNA fragments but does not fix the orientation of the DNA insert or lead to high expression of the foreign protein. This  
20 example describes the construction and characterization of a pair of vaccinia DNA vector genomes v7.5/tk and vEL/tk suitable for direct ligation. The v7.5/tk and vEL/tk vectors were designed to contain unique restriction sites for NotI and ApaI at the beginning of the thymidine kinase gene  
25 allowing the oriented cloning of DNA and eliminating the intact genomes arising from relegation of vaccinia vector arms.

The vNotI/tk vector will only express foreign proteins at the level of the thymidine kinase gene, a weakly  
30 expressed gene only made early during viral infection. To induce high levels of protein expression the sequences encoding for the viral 7.5k promoter and a synthetic EL promoter devised by Chakrabarti and Moss were used to replace the endogenous thymidine kinase promoter. The levels of  
35 expression induced by either promoter was much higher than that observed in vNotI/tk and the promoters were active at all times post infection. These continuous expression

vectors are applicable in cases dependent on early expression, such as T-cell epitope presentation, as well as for bulk expression of proteins.

Use of the thymidine kinase gene as the insertion site for foreign DNA allows implementation of selection protocols for distinguishing recombinants from helper or wild type genomes. The level of tk expression in v7.5/tk and vEL/tk should be much higher than in vaccinia WR or vNot/tk. However, the ApaI site at the beginning of the tk gene in v7.5/tk and vEL/tk was formed from vNot/tk by adding extra nucleotides at the NotI site. The additional nucleotides increase the amino acid sequence at the N terminus of the wild type tk gene from Met-Asn-Gly to Met-Gly-Pro-Ala-Ala-Asn-Gly in v7.5/tk and vEL/tk. Modifications in the expression level and N terminal amino acid sequence of the thymidine kinase gene may increase (more protein) or decrease (different sequence) the sensitivity of the virus to bromodeoxyuridine. Plaques, albeit smaller, were observed with v7.5/tk and vEL/tk infection at a concentration of bromodeoxyuridine sufficient to completely suppress plaque formation for wild type vaccinia WR. Plaque formation was suppressed at five-fold higher concentrations of bromodeoxyuridine, a level of drug that does not interfere with the viability of the cells or impede the ability of tk virus to form plaques. The explanation for the altered sensitivity to bromodeoxyuridine awaits further characterization of the protein as the altered thymidine kinase gene may have a different reaction rate for formation of the triphosphate form of the bromodeoxyuridine or a reduced ability to bind bromodeoxyuridine.

The development of direct ligation vectors has increased the possible applications for poxvirus expression vectors. The v7.5/tk and vEL/tk vectors were designed to incorporate the advantages of oriented cloning, high levels of expression of foreign protein, and the selection for recombinant viruses, into direct ligation vectors. They were shown to express high levels of proteins at all times during

infection. The utility of these vectors was demonstrated by constructing recombinants containing a CTL epitope for ovalbumin (constructed by homologous recombination with a plasmid) or the ovalbumin coding sequence (constructed by  
5 direct ligation protocol) and showing how both recombinants were able to elicit a strong CTL response

The application of these vectors to protocols for construction of complex expression libraries requires efficient production of recombinants and strong selection to  
10 eliminate or minimize wild type and contaminants. The use of two restriction sites allows one to design cloning strategies for the oriented cloning of DNA fragments such as products of PCR (Pfleiderer, et al., 1995, J. General Virology 76:2957-2962) and increases the frequency of the desired recombinant  
15 as wild type genomes can no longer be generated by ligation of vaccinia arms. When v7.5/tk or vEL/tk DNA previously digested with NotI and ApaI was transfected into cells infected with fowlpox the virus titer was one hundred fold lower than for intact uncut DNA. Also, all plaques isolated  
20 in the presence and absence of bromodeoxyuridine (15 with bromodeoxyuridine and 10 without) during the isolation of the vEL/tk-ovaFL contained the ovalbumin insert. The efficiency of infectious virus formation is also increased with the use of fowlpox, helper virus at relatively high moi. Also,  
25 transfection of large DNA fragments varies with the type and preparation of lipid (Miles Carroll, personal communication) and we are presently assaying different lipid mixtures and cell types as well as investigating other parameters to find optimum conditions for the direct ligation protocol. The  
30 v7.5/tk and vEL/tk vectors provide a set of universally applicable direct ligation cloning vectors for poxviruses.

The present invention is not to be limited in scope by the specific embodiments described which are intended as  
35 single illustrations of individual aspects of the invention, and any constructs, viruses or enzymes which are functionally equivalent are within the scope of this invention. Indeed,

various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to  
5 fall within the scope of the appended claims.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be  
10 incorporated by reference.

15

20

25

30

35



WHAT IS CLAIMED IS:

1. A method for identifying a target epitope comprising screening products of an expression library generated from DNA or RNA derived from a cell expressing the target epitope with cytotoxic T cells generated against the cell to identify DNA clones expressing the target epitope.
2. The method of Claim 1 wherein the target epitope is specific to a cell infected with a virus, fungus or mycobacteria.
3. The method of Claim 1 wherein the target epitope is specific to an autoimmune disease.
4. The method of Claim 1 wherein the expression library is constructed in a viral vector infectious for mammalian cells.
5. The method of Claim 4 wherein the viral vector is constructed by trimolecular recombination.
6. The method of Claim 4 wherein the viral vector is a vaccinia viral vector.
7. A method for identifying a tumor specific target epitope comprising screening products of an expression library generated from DNA or RNA derived from a tumor cell expressing the target epitope with cytotoxic T cells generated against the tumor cell to identify DNA clones expressing the target epitope.
8. The method of Claim 7 wherein the cytotoxic T cells react with tumor cells derived from a non-tumorigenic cell line and do not cross-react with the non-tumorigenic cell line.

9. The method of Claim 7 wherein the cytotoxic T cells are derived from animals tolerized with a non-tumorigenic cell line and are then immunized with tumor cells derived from the non-tumorigenic cell line.

5

10. The method of Claim 9 wherein the cytotoxic T cells are derived from animals tolerized with a non-tumorigenic cell line that does not express costimulator activity and are subsequently stimulated with a tumor cell line expressing  
10 costimulator activity.

11. The method of Claim 7 wherein the genes expressed in tumor cells are used to generate HLA restricted cytotoxic T cells which are evaluated for activity against tumor cells.  
15

12. The method of Claim 7 wherein the tumor cell is derived from a single immortalized, non-tumorigenic cell line.

20 13. The method of Claim 12 wherein the screening is performed on a panel of tumor cell lines each derived independently from a single non-tumorigenic cell.

14. The method of Claim 7 wherein the expression  
25 library is constructed in a viral vector infectious for mammalian cells.

15. The method of Claim 14 wherein the viral vector is constructed by trimolecular recombination.  
30

16. The method of Claim 14 wherein the viral vector is a vaccinia viral vector.

17. A method for identifying a target epitope or  
35 antigen comprising:

(a) providing cytotoxic T cells specific for a gene product differentially expressed by a cell expressing the target epitope, and

(b) measuring crossreactivity of the cytotoxic T cells for the cell in which target epitopes are identified as the gene product which induces cytotoxic T cells.

18. The method of Claim 17 wherein the target epitope is specific to a cell infected with a virus, fungus or mycobacteria.

19. The method of Claim 17 wherein the target epitope is specific to an autoimmune disease.

20. The method of Claim 17 wherein a modified differential display method is employed that increases resolution of DNA fragments and reduces the frequency of false positives.

21. The method of Claim 20 further comprising use of the DNA fragments to isolate longer gene products following solution hybridization to single strand circles rescued from a phagemid DNA library.

22. A method for identifying a tumor specific target epitope or antigen comprising:

(a) providing cytotoxic T cells specific for a gene product differentially expressed by a tumor cell expressing the target epitope, and

(b) measuring crossreactivity of the cytotoxic T cells for the tumor cell in which target epitopes are identified as the gene product which induces cytotoxic T cells.

23. The method of Claim 22 wherein the tumor cell is derived from a single immortalized, non-tumorigenic cell line.

24. The method of Claim 22 wherein the assay is performed on a panel of tumor cell lines each derived independently from a single non-tumorigenic cell.

5        25. The method of Claim 22 wherein the generated cytotoxic T cells which react to tumor cells do not react to nontumorigenic T cells.

26. The method of Claim 22 wherein a modified  
10 differential display method is employed that increases resolution of DNA fragments and reduces the frequency of false positives.

27. The method of Claim 26 further comprising use of  
15 the DNA fragments to isolate longer gene products following solution hybridization to single strand circles rescued from a phagemid DNA library.

28. A viral vector containing a DNA insert flanked by  
20 unique sites for restriction enzymes positioned so that religation of the viral vectors arms is prevented and the orientation of the insert DNA is fixed and the DNA insert is operatively associated with a strong regulatory element.

25        29. The viral vector of Claim 28 wherein the vector is constructed by trimolecular recombination.

30        30. The viral vector of Claim 28 wherein the viral vector is a vaccinia viral vector.

31. The vector of Claim 28 in which the vector is derived by recombination with plasmid p7.5/tk (SEQ ID NO: ) or derivatives thereof.

35        32. The vector of Claim 28 in which the vector is derived by recombination with plasmid pEL/tk (SEQ ID NO: ) or derivatives thereof.

33. A viral vector containing a DNA insert flanked by unique sites for restriction enzymes positioned so that religation of the viral vectors arms is prevented and the orientation of the insert DNA is fixed and the DNA insert is  
5 operatively associated with a strong regulatory element wherein the DNA insert encodes a target epitope identified by the method of Claim 1.

34. A viral vector containing a DNA insert flanked by  
10 unique sites for restriction enzymes positioned so that religation of the viral vectors arms is prevented and the orientation of the insert DNA is fixed and the DNA insert is operatively associated with a strong regulatory element wherein the DNA insert encodes a target epitope identified by  
15 the method of Claim 7.

35. The viral vector of Claim 33 or 34 wherein the viral vector is a vaccinia viral vector.

20 36. A vaccinia viral vector containing a DNA insert flanked by unique sites for restriction enzymes positioned so that religation of the viral vectors arms is prevented and the orientation of the insert DNA is fixed and the DNA insert is operatively associated with a strong regulatory element  
25 wherein the DNA insert encodes a target epitope identified by the method of Claim 17.

37. A vaccinia viral vector containing a DNA insert flanked by unique sites for restriction enzymes positioned so  
30 that religation of the viral vectors arms is prevented and the orientation of the insert DNA is fixed and the DNA insert is operatively associated with a strong regulatory element wherein the DNA insert encodes a target epitope identified by the method of Claim 22.  
35

38. The viral vector of Claim 36 or 37 wherein the viral vector is a vaccinia viral vector.

# ABSTRACT OF THE INVENTION

The present invention relates to novel methods for the identification of antigens recognized by cytotoxic T cells (CTLs) and specific for human tumors, cancers, and  
5 infected cells, and the use of such antigens in immunogenic compositions or vaccines to induce regression of tumors, cancers, or infections in mammals, including humans. The invention encompasses methods for induction and isolation of cytotoxic T cells specific for human tumors, cancers and  
10 infected cells, and for improved selection of genes that encode the target antigens recognized by these specific T cells. The invention also relates to differential display methods that improve resolution of, and that reduce the frequency of false positives of DNA fragments that are  
15 differentially expressed in tumorous, cancerous, or infected tissues versus normal tissues. The invention further relates to the engineering of recombinant viruses as expression vectors for tumor, cancer, or infected cell-specific antigens.

20

25

30

35

# DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

## T CELLS SPECIFIC FOR HUMAN TUMORS AND METHODS AND VACCINES BASED THEREON

and for which a patent application:

☒ is attached hereto and includes amendment(s) filed on \_\_\_\_\_ (if applicable)  
☐ was filed in the United States on \_\_\_\_\_ as Application No. \_\_\_\_\_ (for declaration not accompanying application)  
 with amendment(s) filed on \_\_\_\_\_ (if applicable)  
☐ was filed as PCT international Application No. \_\_\_\_\_ on \_\_\_\_\_ and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaanni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Ann L. Gisolfi (Reg. No. 31956), SaraLynn Mandel (Reg. No. 31853), Mark A. Farley (Reg. No. 33170), and James G. Markey (Reg. No. 31636), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

**SEND CORRESPONDENCE TO:** PENNIE & EDMONDS LLP  
1155 AVENUE OF THE AMERICAS  
NEW YORK, N.Y. 10036-2711

**DIRECT TELEPHONE CALLS TO:**  
PENNIE & EDMONDS LLP DOCKETING  
(212) 790-2803

201	FULL NAME OF INVENTOR	LAST NAME ZAUDERER	FIRST NAME MAURICE	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY ROCHESTER	STATE OR FOREIGN COUNTRY NEW YORK	COUNTRY OF CITIZENSHIP USA	
	POST OFFICE ADDRESS	STREET 44 WOODLAND ROAD	CITY PITTSFORD	STATE OR COUNTRY NEW YORK	ZIP CODE 14534
202	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
203	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
DATE	DATE	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE



### 7.5 k promoter

GGCCAAAAATTGAAAACTAGATCTTTTATTCACGGGGCCGCCATG GGC CCG GCC GCC AAC GGC GGA  
Met Gly Pro Ala Ala Asn Gly Gly

tk coding sequence

**synthetic E/L promoter**

Not I      Apa I

GGCCAAAAATGAAATTTATTTTTTTTGGAAATATAAAGCCGGCCGCAAGGCCCCGCCGCCAACGCCGGA  
Met Gly Pro Ala Ala Asn Gly Gly

tk coding sequence

## FIGURE 1

GGGCCCGGCC-3'

## FIGURE 2

[illegible]

START

CODON BAMHI SMAI PSTI

## TRANSCRIPTION

**STOP SIGNAL**

GGGCCCGGCC-3'

**FIGURE 2 (CONT)**

[illegible]

START

5'-GGCCAAATTTGAAAAC TAGATCTATTATTCACGCCGCCCGCA TTGAGTGATCCCCCGGCTGCAGGA

TTGGATATCAAGCTTATGATACCGTTCGACCTCGAGGGGGGGCTAACTAACTAATTTGTTTGT

GGGCCCGGCC-3'

**FIGURE 2 (CONT)**

Figure 1. The structure of the *hsp70* gene. The exons are numbered 1 to 5. The introns are numbered 1 to 4. The size of the exons and introns is indicated in base pairs (bp). The size of the gene is indicated in base pairs (bp). The size of the gene is indicated in base pairs (bp).

START

PSTI

TRANSCRIPTION

# STOP SIGNAL

TTGGATATCAAGCTTATCGATACCGTTCGACCTCGAGGGGGGGCTAACTAACTAATTTGTTTGT

GGGCCCGGCC-3'

**FIGURE 2 (CONT)**

Figure 1 consists of 12 subplots (a-l) showing the time course of various physiological and behavioral parameters during a 12-hour shift. The x-axis for all plots is 'Time (h)' from 0 to 12. The y-axis for each plot represents a specific parameter. The parameters are: (a) HR (b/min), (b) BP (mmHg), (c) RR (1/min), (d) SpO2 (%), (e) Tsk (°C), (f) Trect (°C), (g) Tsk/Trect (°C), (h) Tsk/Trect (°C), (i) Tsk/Trect (°C), (j) Tsk/Trect (°C), (k) Tsk/Trect (°C), and (l) Tsk/Trect (°C). The plots show that heart rate, blood pressure, and respiratory rate generally increase over time, while skin temperature and rectal temperature decrease. The Tsk/Trect ratio remains relatively stable around 1.0.




FIGURE 3




FIGURE 4




FIGURE 5







FIGURE 6

a b c d e




- a. B/c.N
- b. BCB 13
- c. BCA 22
- d. BCA 34
- e. BCA 39

PCR amplification with  
primers MR\_1 + MR\_5.

Bands 1 to 4 are  
examples of  
differential display  
in tumors.

FIGURE 7

A.



B.




FIGURE 8

2025/05/20 14:55:30




FIGURE 9




FIGURE 10

A




FIGURE 11

B




FIGURE 11




FIGURE 12



### B-Glucoronidase Analysis of Recombinant Viruses




FIGURE 13




FIGURE 14